第79回日本血液学会学術集会 My Schedule

The preclinical study of iPSC-derived CTL therapy with a safeguard system

[演者] Miki Ando (安藤 美樹):1,2
[著者] Hiromitsu Nakauchi (中内 啓光):2,3
1:Transfusion Medicine and Stem Cell Regulation, Juntendo University, Japan, 2:Stem Cell Therapy, The Institute of Medical Science, Tokyo University, Japan, 3:Stem Cell Biology and Regenerative Medicine, Stanford University, USA

Clinical development of de-fucosylated anti-CCR4 and CD 4 antibodies for the treatment of cancer

[演者] Kouji Matsushima (松島 綱治):1
1:Mol. Preventive Med., The University of Tokyo, Tokyo, Japan

Personalized modulation of tumor immune-microenvironments for development of effective combination immunotherapy

[演者] Yutaka Kawakami (河上 裕):1
1:Institute for Advanced Medical Research, Keio University School of Medicine, Japan

The tumor microenvironment in B cell lymphomas

[演者] Christian G. Steidl:1,2
1:Lymphoid Cancer Research, BC Cancer Agency, Vancouver, Canada, 2:Pathology, University of British Columbia, Vancouver, Canada

Regulation of fetal hemoglobin expression by the LRF transcription factor

[演者] Takahiro Maeda (前田 高宏):1
1:Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

Ineffective erythropoiesis in myelodysplastic syndrome

[演者] Atsushi Iwama (岩間 厚志):1
1:Dept. Cell. Mol. Med., Graduate School of Medicine, Chiba University, Japan

Hemoglobinopathy in Southeast Asia

[演者] Suthat Fucharoen:1
[著者] Pranee Winichagoon:1
1:Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya Campus, Nakornpathom, Thailand

The role of iron in ineffective erythropoiesis

[演者] Clara Camaschella:1
[著者] Alessia Pagani:1, Laura Silvestri:1, Antonella Nai:1
1:Vita Salute University and San Raffaele Scientific Institute, Milano, Italy

The optimal plasma lenalidomide concentration and the function of NK cell in Ld therapy for MM

[演者] Takahiro Kobayashi (小林 敬宏):1
[著者] Masatomo Miura (三浦 昌朋):2, Takenori Niioka (新岡 丈典):2, Yuki Fujioka (藤岡 優樹):1,3, Maiko Abumiya (鐙屋 舞子):2, Hideaki Ohyagi (大八木 秀明):4, Yoshinori Shinohara (篠原 良徳):4, Mutsuhito Motegi (茂木 睦仁):5, Jun Kuroki (黒木 淳):6, Tamio Nishinari (西成 民夫):6, Yoshinari Kawabata (川端 良成):7, Atsushi Kitabayashi (北林 淳):7, Yoshihiro Michishita (道下 吉広):8, Sho Ikeda (池田 翔):1, Seiji Shida (志田 青慈):1, Tomoko Yoshioka (吉岡 智子):1, Hiroyoshi Nishikawa (西川 博嘉):3, Naoto Takahashi (高橋 直人):1
1:Hematol., Akita Univ., Akita, Japan, 2:Pharmacy, Akita Univ. Hosp., Akita, Japan, 3:Cancer Immunol., National Cancer Center, Chiba, Japan, 4:Hematol., Hiraka General Hosp., Akita, Japan, 5:Int Med., Omagari Kousei Medical Center, Akita, Japan, 6:Int. Med., Yuri Kumiai General Hospital, Akita, Japan, 7:Hematol., Akita Kousei Medical Center, Akita, Japan, 8:Hematol., Nohshiro Kousei Medical Center, Akita, Japan

Analysis of NK cell function in multiple myeloma patients

[演者] Shotaro Hagiwara (萩原 將太郎):1
[著者] Noriko Toyama-Sorimachi (反町 典子):2, Junji Tanaka (田中 淳司):1
1:Hematology, Tokyo Women's Medical Univ., Tokyo, Japan, 2:Reserch Institute, National Center for Global Health and Medicine

Comparison of MRD detection in autografts of multiple myeloma patients between EuroFlow and NGS

[演者] Hiroyuki Takamatsu (高松 博幸):1
[著者] Naoki Takezako (竹迫 直樹):2, Rachel Wee:1, Takeshi Yoroidaka (鎧高 健志):1, Takeshi Yamashita (山下 剛史):1,3, Ryoichi Murata (村田 了一):3, Jianbiao Zheng:4, Martin Moorhead:4, Victoria Carlton:4, Malek Faham:4, Shinji Nakao (中尾 眞二):1
1:Hematol. Kanazawa Univ., Kanazawa, Japan, 2:Disaster Medical Center of Japan, Tachikawa, Japan, 3:Keiju Kanazawa Hospital, Kanazawa, Japan, 4:Adaptive Biotechnologies Corp., South San Francisco, CA

Potent anti-tumor effect of combination therapy using AKT inhibitor and pomalidomide with DEX in MM

[演者] Shiori Kinoshita (木下 史緒理):1
[著者] Masaki Ri (李 政樹):1, Takashi Yoshida (吉田 嵩):1, Tomoko Narita (成田 朋子):1, Haruhito Totani (戸谷 治仁):1, Ashour Reham:1,2, Asahi Ito (伊藤 旭):1, Shigeru Kusumoto (楠本 茂):1, Takashi Ishida (石田 高司):1, Hirokazu Komatsu (小松 弘和):1, Shinsuke Iida (飯田 真介):1
1:Department of Hematology and Oncology, Nagoya City Univ., Nagoya, Japan, 2:Clinical Pathology, Qena University Hospital, South Valley University, Qena, Egypt

Cereblon-independent anti-myeloma pathway of TC11, a novel compound of immunomodulatory drugs

[演者] Misa Nakamura (中村 美沙):1
[著者] Daiju Ichikawa (市川 大樹):1, Shuji Aida (會田 宗司):1, Nahoko Hashimoto (橋本 菜帆子):1, Wakana Murota (室田 若菜):1, Ryo Uozaki (宇於崎 涼):1, Mikio Okayama (岡山 幹夫):2, Kota Fujimori (藤森 宏太):1, Yuko Yonemura (米村 裕子):3, Noriko Tabata (田畠 典子):3, Hiroshi Yanagawa (柳川 弘志):3, Maiko Matsushita (松下 麻衣子):1, Yutaka Hattori (服部 豊):1
1:Clin. Physiol. & Therapeutics, Keio Faculty of Pharmacy, Tokyo, Japan, 2:Division of Hematology, Keio University School of Medicine, Tokyo, Japan, 3:IDAC Theranostics Inc., Tokyo, Japan

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia

[演者] Feng-Ming Tien:1
[著者] Hsin-An Hou:1, Chien-Yuan Chen:1, Wen-Chien Chou:2, Jih-Luh Tang:1, Hwei-Fang Tien:1
1:Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2:Departments of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Analyze 36 fusion genes in 6170 de novo acute leukemia and myeloid neoplasms cases during 14 years

[演者] Xue Chen:1
[著者] Wen Teng:1, Lei Guo:1, Xiaoli Ma:1, Fang Wang:1, Yang Zhang:1, Ying Zhang:2, Ping Zhu:2, Hongxing Liu:1
1:Beijing Lu Daopei Hospital, Beijing, China, 2:Department of Hemotology, Peking University First Hospital, Beijing, China

Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

[演者] Kiyomi Morita (森田 聖美):1,2
[著者] Feng Wang:1, Keyur Patel:1, Carlos Bueso-Ramos:1, Abdallah Abou Zhar:1, Curtis Gumbs:1, Latasha Little:1, Samantha Tippen:1, Rebecca Thornton:1, Marcus Coyle:1, Jianhua Zhang:1, Xingzhi Song:1, Marisela Mendoza:1, Chang-Jiun Wu:1, Steven Kornblau:1, Courtney Dinardo:1, Farhad Ravandi:1, Guillermo Garcia-Manero:1, Elias Jabbour:1, Michael Andreeff:1, Hagop Kantarjian:1, Jorge E. Cortes:1, Marina Konopleva:1, Andrew Futreal:1, Koichi Takahashi (高橋 康一):1
1:The University of Texas MD Anderson Cancer Center, Houston, USA, 2:Department of Hematology and Oncology, The University of Tokyo

Genetic landscape of acute erythroid leukemia

[演者] June Takeda (竹田 淳恵):1,8
[著者] Lee-Yung Shih:2, Kenichi Chiba (千葉 健一):3, Yuichi Shiraishi (白石 友一):3, Yusuke Shiozawa (塩澤 裕介):4, Hideki Makishima (牧島 秀樹):1, Tetsuichi Yoshizato (吉里 哲一):1, Yasunobu Nagata (永田 安伸):5, Akira Hangaishi (半下石 明):6, Ken Ishiyama (石山 謙):7, Akifumi Takaori-Kondo (高折-近藤 晃史):8, Keisuke Kataoka (片岡 圭亮):1, Masashi Sanada (真田 昌):9, Hiroko Tanaka (田中 洋子):3, Kensuke Usuki (臼杵 憲祐):6, Shuichi Miyawaki (宮脇 修一):10, Satoru Miyano (宮野 悟):3, Arnold Ganser:11, Michael Heuser:11, Seishi Ogawa (小川 誠司):1, Felicitas Thol:11, Kenichi Yoshida (吉田 健一):1
1:Dept. of Pathology and Tumor Biology, Kyoto Univ., Kyoto, Japan, 2:Division of Hematology-Oncology, Chang Gung University, Taoyuan, Taiwan, 3:Human Genome Center, The University of Tokyo, Tokyo, Japan, 4:Dept. of Pediatrics, The University of Tokyo, Tokyo, Japan, 5:Dept. of Translational Hematology and Oncology, Cleveland Clinic, OH, US, 6:Dept. of Hematology, NTT Medical Center, Tokyo, Japan, 7:Dept. of Hematology, Kanazawa University, Kanazawa, Japan, 8:Dept. of Hematology/Oncology, Kyoto University, Kyoto, Japan, 9:Dept. of Advanced Diagnosis, Nagoya Medical Center, Nagoya, Japan, 10:Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 11:Dept. of Hematology, Oncology and SCT, Hannover Medical School, Germany

Clinical significance and association of other gene aberrations of PTPN11 mutations in pediatric AML

[演者] Genki Yamato (大和 玄季):1,2,3
[著者] Norio Shiba (柴 徳生):1,3,4, Yusuke Hara (原 勇介):1,2,3, Kentaro Ohki (大木 健太郎):1,3,5, Jun Okubo (大久保 淳):1,3, Myoung-Ja Park (朴 明子):1,3, Manabu Sotomatsu (外松 学):1,3, Hirokazu Arakawa (荒川 浩一):2, Nobutaka Kiyokawa (清河 信敬):3,5, Daisuke Tomizawa (富澤 大輔):3,6, Keizo Horibe (堀部 敬三):3,7, Souichi Adachi (足立 壮一):3,8, Takashi Taga (多賀 崇):3,9, Yasuhide Hayashi (林 泰秀):1,3,10
1:Dept. Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan, 2:Dept. Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan, 3:Japan Children's Cancer Group, Japan, 4:Dept. Pediatrics, Yokohama City University Hospital, Kanagawa, Japan, 5:Natl. Cent. for Child Health and Dev., Tokyo, Japan, 6:Div. Leukemia and Lymphoma, Children's Cancer Center, NCCHD, Tokyo, Japan, 7:Clinical Research Center, National Hospital Organization Nagoya Medical Center, Aichi, Japan, 8:Human Health Science, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 9:Dept. Pediatrics, Shiga University of Medical Science, Shiga, Japan, 10:Japanese Red Cross Gunma Blood Center, Gunma, Japan

Inhibition of microRNA-138 promotes osteogenic differentiation in stromal cells in multiple myeloma

[演者] Shokichi Tsukamoto (塚本 祥吉):1,2
[著者] Marianne B. Loevendorf:2, Jihye Park:2, Karma Z. Salem:2, Salomon Manier:2, Michaela R. Reagan:2, Oksana Zavidij:2, Mahshid Rahmat:2, Satoshi Takagi (高木 聡):2, Yawara Kawano (河野 和):2,6, Katsutoshi Kokubun (國分 克寿):2, Andreas Petri:3,4, Aldo M. Roccaro:2, Marzia Capelletti:2, Chiaki Nakaseko (中世古 知昭):1,5, Emiko Sakaida (堺田 惠美子):1, Sakari Kauppinen:3,4, Irene M. Ghobrial:2
1:Department of Hematology, Chiba University Hospital, Chiba, Japan, 2:Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA, 3:Center for RNA Medicine, Aalborg University Campus Copenhagen, Copenhagen, Denmark, 4:Department of Haematology, Aalborg University Hospital, Aalborg, Denmark, 5:Department of Hematology, International University of Health and Welfare, 6:Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan

TAK1 inhibition subverts TRAIL-induced osteoclastogenesis and potentiates its anti-myeloma action

[演者] Hirofumi Tenshin (天真 寛文):1
[著者] Jumpei Teramachi (寺町 順平):3, Asuka Oda (小田 明日香):2, Ryota Amachi (天知 良太):1, Masahiro Hiasa (日浅 雅博):4, Keiichiro Watanabe (渡邉 佳一郎):1, Bat-Erdene Ariunzaya:2, Masami Iwasa (岩佐 昌美):2, Shiro Fujii (藤井 志朗):2, Kumiko Kagawa (賀川 久美子):2, Takeshi Harada (原田 武志):2, Masahiro Oura (大浦 雅博):2, Yusaku Maeda (前田 悠作):2, Shingen Nakamura (中村 信元):2, Hirokazu Miki (三木 浩和):5, Itsuro Endo (遠藤 逸朗):2, Eiji Tanaka (田中 栄二):1, Toshio Matsumoto (松本 俊夫):6, Masahiro Abe (安倍 正博):2
1:Department of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School, 2:Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School, 3:Department of Histology and Oral Histology, Tokushima University Graduate School, 4:Department of Biomaterials and Bioengineering, Tokushima University Graduate School, 5:Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, 6:Fujii Memorial Institute of Medical Sciences, Tokushima University

A novel dual inhibitor(PI3K/HDAC), CUDC-907, and combination with carfilzomib inhibits myeloma cells

[演者] Yuko Tanaka (田中 裕子):1
[著者] Seiichi Okabe (岡部 聖一):1, Tetsuzo Tauchi (田内 哲三):1, Kazuma Ohyashiki (大屋敷 一馬):1
1:Division of Hematology, Tokyo Medical University, Tokyo, Japan

The HIF-1α-KDM3A-MALAT1 positive feedback loop contribute to myeloma survival in hypoxic environment

[演者] Sho Ikeda (池田 翔):1
[著者] Akihiro Kitadate (北舘 明宏):1, Fumito Abe (阿部 史人):1, Naoto Takahashi (高橋 直人):1, Hiroyuki Tagawa (田川 博之):1
1:Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan

Mature osteoblasts reduce Pim-2 to cause an energy crisis in myeloma cells

[演者] Shingen Nakamura (中村 信元):1
[著者] Hirokazu Miki (三木 浩和):2, Hirofumi Tenshin (天真 寛文):1,3, Keiichiro Watanabe (渡邉 佳一郎):3, Jumpei Teramachi (寺町 順平):4, Masahiro Hiasa (日浅 雅博):5, Asuka Oda (小田 明日香):1, Yusaku Maeda (前田 悠作):1, Masahiro Oura (大浦 雅博):1, Mamiko Takahashi (高橋 真美子):1, Masami Iwasa (岩佐 昌美):1, Takeshi Harada (原田 武志):1, Shiro Fujii (藤井 志朗):1, Kumiko Kagawa (賀川 久美子):1, Masahiro Abe (安倍 正博):1
1:Department of Hematology, Endocrinology and Metabolism, Tokushima Univ., Tokushima, Japan, 2:Department of Transfusion Medicine and Cell Therapy, Tokushima, Japan, 3:Department of Orthodontics and Dentofacial Orthopedics, Tokushima Univ., Tokushima, Japan, 4:Department of Histology and Oral Histology, Tokushima Univ., Tokushima, Japan, 5:Department of Biomaterials and Bioengineering, Tokushima Univ., Tokushima, Japan

RUNX cluster regulation by GENE SWITCH triggers a profound tumor regression of diverse origins

[演者] Ken Morita (森田 剣):1
[著者] Kensho Suzuki (鈴木 健聖):1, Shintaro Maeda (前田 信太郎):1, Yoshihide Mitsuda (光田 吉秀):1, Chieko Tokushige (徳重 智恵子):1, Gengo Kashiwazaki (柏崎 玄伍):2, Junichi Taniguchi (谷口 純一):2, Rina Maeda (前田 里菜):2, Mina Noura (能浦 三奈):1, Masahiro Hirata (平田 勝啓):3, Tatsuki Kataoka (片岡 竜貴):3, Hiroki Kiyose (清瀬 大樹):1, Mayu Tokumasu (徳舛 麻友):1, Hidemasa Matsuo (松尾 英将):1, Akihiko Matsuo (松尾 明彦):1, Sunao Tanaka (田中 直):1, Yasushi Okuno (奥野 恭史):1, Manabu Muto (武藤 学):4, Kazuhito Naka (仲 一仁):5, Kosei Ito (伊藤 公成):6, Toshio Kitamura (北村 俊雄):7, Yasufumi Kaneda (金田 安史):8, Paul P. Liu:9, Toshikazu Bando (板東 俊和):2, Hiroshi Sugiyama (杉山 弘):2, Yasuhiko Kamikubo (上久保 靖彦):1, Souichi Adachi (足立 壮一):1,10
1:Dept. of Human Health Sciences, Kyoto Univ., Kyoto, Japan, 2:Dept. of Chemistry, Kyoto Univ., Kyoto, Japan, 3:Dept. of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan, 4:Dept. of Therapeutic Oncology, Kyoto University, Kyoto, Japan, 5:Hiroshima Univ., Hiroshima, Japan, 6:Dept. of Molecular Bone Biology, Nagasaki University, Nagasaki, Japan, 7:Inst. of Medical Science, The Univ. of Tokyo, Tokyo, Japan, 8:Dept. of Genome Biology, Osaka University, Osaka, Japan, 9:Oncogenesis and Development Section, NHGRI, NIH, Bethesda, USA, 10:Dept. of Pediatrics, Kyoto University, Kyoto, Japan

FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase

[演者] Keigo Okada (岡田 啓五):1
[著者] Ayako Nogami (野上 彩子):1, Cheng Chen (陳 城):1, Maho Kawakami (川上 真帆):1, Hiroki Akiyama (秋山 弘樹):1, Shinya Ishida (石田 信也):1, Yoshihiro Umezawa (梅澤 佳央):1, Osamu Miura (三浦 修):1
1:Dept. of Hematol., Tokyo Medical and Dental Univ., Tokyo, Japan

RUNX1 enhances leukemia cell engraftment in the vascular niche through up-regulating E-selectin

[演者] Chieko Tokushige (徳重 智恵子):1
[著者] Ken Morita (森田 剣):1, Shintaro Maeda (前田 信太郎):1, Hiroki Kiyose (清瀬 大樹):1, Mina Noura (能浦 三奈):1, Toshikazu Bando (板東 俊和):2, Masahiro Hirata (平田 勝啓):3, Tatsuki Kataoka (片岡 竜貴):3, Hiroshi Sugiyama (杉山 弘):2, Yasuhiko Kamikubo (上久保 靖彦):1, Souichi Adachi (足立 壮一):1,4
1:Dept. of Human Health Science, Kyoto Univ., Kyoto, Japan, 2:Dept. of Chemistry, Kyoto Univ., Kyoto, Japan, 3:Dept. of Diagnostic Pathology, Kyoto Univ., Kyoto, Japan, 4:Dept. of Pediatrics, Kyoto Univ., Kyoto, Japan

Targeting nuclear RNA metabolic pathways for the treatment of acute myeloid leukemia

[演者] Takuji Yamauchi (山内 拓司):1,2
[著者] Takeshi Masuda (増田 毅):3, Manami Maeda (前田 真奈美):1, Matthew C. Canver:4, Michael Seiler:5, Mohammad Shboul:6, Yuichiro Semba (仙波 雄一郎):2, Yuichi Ishikawa (石川 祐一):1, Michitaka Nakano (中野 倫考):2, Hai Yi:1, Stuart H. Orkin:4, Bruno Reversade:6, Silvia Buonamici:5, Luca Pinello:7, Daniel E. Bauer:4, Koichi Akashi (赤司 浩一):1,8, Takahiro Maeda (前田 高宏):1,8
1:Department of Medicine, Brigham and Womens Hospital, Boston, Massachusetts, USA, 2:Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 3:Department of Pharmaceutical Microbiology, Kumamoto University, Kumamoto, Japan, 4:Division of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, 5:H3 Biomedicine, Inc., Cambridge, MA, USA, 6:Institute of Medical Biology, A*STAR, 8A Biomedical Grove, Singapore, 7:Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts, USA, 8:Center for Cellular and Molecular Medicine, Kyushu University, Fukuoka, Japan

Withdrawn

Frequent somatic alterations involving programmed death ligands in EBV-related lymphomas

[演者] Keisuke Kataoka (片岡 圭亮):1,2
[著者] Hiroaki Miyoshi (三好 寛明):3, Ayako Demachi-Okamura (岡村 文子):4, Seiji Sakata (坂田 征士):5, Lucile Couronne:6,7, Yasunori Kogure (木暮 泰寛):1, Akito Dobashi (土橋 映仁):5, Yasuharu Sato (佐藤 康晴):8, Kenji Nishida (西田 賢司):8, Yuichi Shiraishi (白石 友一):9, Hiroko Tanaka (田中 洋子):9, Kenichi Chiba (千葉 健一):9, Yosaku Watatani (綿谷 陽作):1, Yusuke Shiozawa (塩澤 裕介):1, Kenichi Yoshida (吉田 健一):1, Masashi Sanada (真田 昌):10, Motohiro Kato (加藤 元博):11, Kiyotaka Kuzushima (葛島 清隆):4, Satoru Miyano (宮野 悟):9, Yasunori Ota (大田 泰徳):12, Koji Izutsu (伊豆津 宏二):13, Tadashi Yoshino (吉野 正):8, Olivier Hermine:6,7, Kengo Takeuchi (竹内 賢吾):5, Yoshiki Akatsuka (赤塚 美樹):4,14, Koichi Ohshima (大島 孝一):3, Seishi Ogawa (小川 誠司):1
1:Dept. Pathol. Tum. Biol., Kyoto Univ., Kyoto, Japan, 2:Div. Mol. Oncol., Natl. Cancer Cent. Res. Inst., Tokyo, Japan, 3:Dept. Pathol., Kurume Univ. Sch. Med., Kurume, Japan, 4:Div. Immunol., Aichi Cancer Cent. Res. Inst., Nagoya, Japan, 5:Pathol. Proj. Mol. Target, Cancer Inst., Tokyo, Japan, 6:Dept. Clin. Hematol., Necker Hosp., AP-HP, Paris, France, 7:Imagine Inst., Paris, France, 8:Dept. Pathol., Okayama Univ., Okayama, Japan, 9:Human Genome Cent., Inst. Med. Sci., Univ. Tokyo, Tokyo, Japan, 10:Dept. Advanced Diag., Nagoya Med. Cent., Nagoya, Japan, 11:Children Cancer Cent., Natl. Cent. Child Health Develop, Tokyo, Japan, 12:Dept. Pathol., Toranomon Hosp., Tokyo, Japan, 13:Dept. Hematol., Natl. Cancer Cent. Hosp., Tokyo, Japan, 14:Dept. Hematol., Fujita Health Univ., Toyoake, Japan

Combination of Tet2 loss-of-function and RHOAG17V expression leads to T-cell lymphoma in mice

[演者] Tran B. Nguyen:1,2,3
[著者] Mamiko Sakata-Yanagimoto:4,5, Manabu Fujisawa:1, Shigeru Chiba:4,5
1:Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan, 2:Department of Hematology, Falcuty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, 3:Stem Cell Transplantation Zone, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Vietnam, 4:Department of Hematology, Falcuty of Medicine, University of Tsukuba, Ibaraki, Japan, 5:Department of Hematology, University of Tsukuba Hospital, Ibaraki, Japan

Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma

[演者] Manabu Fujisawa (藤澤 学):1
[著者] Mamiko Sakata-Yanagimoto (坂田-柳元 麻実子):1, Kota Fukumoto (福本 浩太):1, Daisuke Komori (小森 大輔):1, Shoko Nishizawa (西澤 翔子):1, Swarna Tanzima:1, Maiko Kiryu (桐生 真依子):1, Terukazu Enami (榎並 輝和):1, Masafumi Muratani (村谷 匡史):2, Kenichi Yoshida (吉田 健一):3, Seishi Ogawa (小川 誠司):3, Kosei Matsue (末永 孝生):4, Naoya Nakamura (中村 直哉):5, Kengo Takeuchi (竹内 賢吾):6, Koji Izutsu (伊豆津 宏二):7, Katsuya Fujimoto (藤本 勝也):8, Takanori Teshima (豊嶋 崇徳):8, Hiroaki Miyoshi (三好 寛明):9, Koichi Ohshima (大島 孝一):9, Shigeru Chiba (千葉 滋):1
1:Department of Hematology, University of Tsukuba, Ibaraki, Japan, 2:Department of Genome Biology, University of Tsukuba, Ibaraki, Japan, 3:Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 4:Hematology/Oncology Department, Kameda Medical Center, Chiba, Japan, 5:Department of Pathology, Tokai University School of Medicine, Isehara, Japan, 6:Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan, 7:Department of Hematology, Toranomon Hospital, Tokyo, Japan, 8:Department of Hematology, Hokkaido University, Sapporo, Japan, 9:Department of Pathology, Kurume University, Kurume, Japan

Integrated analysis of primary central nervous system lymphoma

[演者] Kenichi Yoshida (吉田 健一):1
[著者] Yotaro Ochi (越智 陽太郎):1, Yuichi Shiraishi (白石 友一):2, Yusuke Okuno (奥野 友介):3, Tomoya Isobe (磯部 知弥):4, Hiromichi Suzuki (鈴木 啓道):1, Azusa Hayano (早野 あずさ):5, Jumpei Homma (本間 順平):6, Hiroaki Hondoh (本道 洋昭):6, Junya Fukai (深井 順也):7, Koji Kajiwara (梶原 浩司):8, Makoto Ideguchi (出口 誠):8, Yoshihiro Komohara (菰原 義弘):9, Naoki Yajima (矢島 直樹):10, Naoto Tsuchiya (土屋 尚人):10, Masakazu Sano (佐野 正和):10, Yasuo Iwadate (岩立 康男):11, Kenichi Chiba (千葉 健一):2, Ai Okada (岡田 愛):2, Hiroko Tanaka (田中 洋子):2, Satoru Miyano (宮野 悟):2, Ryuya Yamanaka (山中 龍也):5, Seishi Ogawa (小川 誠司):1
1:Dept. of Pathology and Tumor Biology, Kyoto Univ., Kyoto, Japan, 2:Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 3:Dept. of Pediatrics, Nagoya University, Nagoya, Japan, 4:Dept. of Pediatrics, The University of Tokyo, Japan, 5:Kyoto Prefectural University of Medicine, Kyoto, Japan, 6:Department of Neurosurgery, Toyama Prefectural Central Hospital, Toyama, Japan, 7:Dept. of Neurological Surgery, Wakayama Medical University, Wakayama, Japan, 8:Dept. of Neurosurgery, Yamaguchi University, Yamaguchi, Japan, 9:Department of Cell Pathology, Kumamoto University, Kumamoto, Japan, 10:Department of Neurosurgery, Niigata University, Niigata, Japan, 11:Department of Neurosurgery, Chiba University, Chiba, Japan

Targeted sequencing of primary central nervous system lymphoma (PCNSL)

[演者] Keiichiro Hattori (服部 圭一朗):1
[著者] Mamiko Sakata-Yanagimoto (坂田-柳元 麻実子):1,2, Yasuhito Suehara (末原 泰人):1, Yasuhisa Yokoyama (横山 泰久):1, Takayasu Kato (加藤 貴康):1,2, Naoki Kurita (栗田 尚樹):2, Naoshi Obara (小原 直):1,2, Yuichi Hasegawa (長谷川 雄一):2, Shigeru Chiba (千葉 滋):1,2
1:Hematol., University of Tsukuba, Ibaraki, Japan, 2:Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Novel therapeutic strategies for multiple myeloma

[演者] Shaji Kumar:1
1:Mayo Clinic, USA

Therapeutic approach for T-cell lymphoma

[演者] Steven M. Horwitz:1
1:Memorial Sloan Kettering Cancer Center, USA

New therapeutic developments in multiple myeloma

[演者] Pieter Sonneveld:1
1:Professor of Hematology, Erasmus MC Rotterdam, The Netherlands

MDS: how close are we to a precision medicine approach?

[Speaker] Stephen D. Nimer:1
1:Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine

Genomic and Treatment Advances in Waldenström’s Macroglobulinemia

[Speaker] Steven P. Treon:1
1:Bing Center for Waldenström’s Macroglobulinemia, Department of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School

New Horizons in the Treatment of Hodgkin Lymphoma

[Speaker] Andreas Engert:1
1:German Hodgkin Study Group (GHSG), Department of Internal Medicine I, University Hospital of Cologne

The Positioning of Daratumumab in Relapsed/Refractory Multiple Myeloma (rrMM) in Clinical Practices

[Speaker] Torben Plesner:1
1:University of Southern Denmark Institute of Regional Health Science Department of Hematology Section of Internal Medicine Vejle Hospital

Evolution of the term preleukemia

[演者] H. Phillip Koeffler:1,2,3
[著者] Geraldine Leong:1
1:Cancer Science Institute of Singapore, National University of Singapore, Singapore, 2:National University Cancer Institute of Singapore, National University Hospital, Singapore, 3:Cedars-Sinai Medical Center, Los Angeles, USA

Application of super-enhancer profiling to the understanding of molecular pathogenesis and the identification of novel therapeutic targets in T-cell leukemia

[演者] Takaomi Sanda (三田 貴臣):1
1:Cancer Science Institute of Singapore, National University of Singapore, Singapore

Metabolism, control of cell fate decisions, and stem cell renewal

[演者] Keisuke Ito (伊藤 圭介):1
1:Albert Einstein College of Medicine, NY, USA

Hormonal regulation of hematopoietic stem cell

[演者] Daisuke Nakada (中田 大介):1
1:Baylor College of Medicine, Houston, TX, USA

Hematopoietic stem cell (HSC)-independent hematopoiesis and HSC diversity in the mouse embryo

[演者] Momoko Yoshimoto (吉本 桃子):1
1:Center for Stem Cell Research, IMM, McGovern Medical School, UTHealth at Houston, TX, USA

Transcription-based therapies for acute myeloid leukemia

[演者] Susumu Kobayashi (小林 進):1
1:Beth Israel Deaconess Medical Center, Boston, MA, USA

Integrated molecular profiling of juvenile myelomonocytic leukemia

[演者] Norihiro Murakami (村上 典寛):1
[著者] Yusuke Okuno (奥野 友介):1, Kenichi Yoshida (吉田 健一):2, Yuichi Shiraishi (白石 友一):3, Genta Nagae (永江 玄太):5, Kyogo Suzuki (鈴木 喬悟):1, Atsushi Narita (成田 敦):1, Hirotoshi Sakaguchi (坂口 大俊):6, Nozomu Kawashima (川島 希):1, Xinan Wang (王 希楠):1, Yinyan Xu (徐 銀燕):1, Kenichi Chiba (千葉 健一):3, Hiroko Tanaka (田中 洋子):3, Asahito Hama (濱 麻人):1, Masashi Sanada (真田 昌):2, Masashi Hirayama (平山 雅士):4, Arata Watanabe (渡辺 新):4, Toshihide Ueno (上野 敏秀):7, Seiji Kojima (小島 勢二):1, Hiroyuki Aburatani (油谷 浩幸):5, Hiroyuki Mano (間野 博行):7, Satoru Miyano (宮野 悟):3, Seishi Ogawa (小川 誠司):2, Yoshiyuki Takahashi (高橋 義行):1, Hideki Muramatsu (村松 秀城):1
1:Department of Pediatrics, Nagoya University, Nagoya, Japan, 2:Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 3:Human Genome Center, Tokyo University, Tokyo, Japan, 4:Deparment of Pediatrics, Nakadori General Hospital, Akita, Japan, 5:Genome Science Division, Tokyo University, Tokyo, Japan, 6:Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Japan, 7:Department of Cellular Signaling, Tokyo University, Tokyo, Japan

Gene expression-based classification of myelodysplasia with biological and clinical relevance

[演者] Yusuke Shiozawa (塩澤 裕介):1
[著者] Luca Malcovati:2, Anna Galli:2, Andrea Pellagatti:3, Mohsen Karimi:4, Aiko Sato (佐藤 亜以子):1, Yusuke Sato (佐藤 悠佑):1, Hiromichi Suzuki (鈴木 啓道):1, Tetsuichi Yoshizato (吉里 哲一):1, Kenichi Yoshida (吉田 健一):1, Yuichi Shiraishi (白石 友一):5, Kenichi Chiba (千葉 健一):5, Hideki Makishima (牧島 秀樹):1, Jacqueline Boultwood:3, Eva Hellstrom-Lindberg:4, Satoru Miyano (宮野 悟):5,6, Mario Cazzola:2, Seishi Ogawa (小川 誠司):1
1:Tumor Biology, Kyoto Univ., Kyoto, 2:Dept. of Molecular Medicine, Pavia Univ., Pavia, Italy, 3:Bloodwise Molecular Haematology Unit, Oxford Univ., Oxford, United Kingdom, 4:Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden, 5:Lab. DNA Information Analysis, Inst. Medical Science, Tokyo Univ., Tokyo, 6:Lab. Sequence Analysis, Inst. Medical Science, Tokyo Univ., Tokyo

Mechanisms of the clonal evolution of MDS as revealed by single-cell sequencing

[演者] Masahiro Nakagawa (中川 正宏):1,2
[著者] Ryosaku Inagaki (稲垣 良作):1,2,3, Yasuhito Nannya (南谷 泰仁):1, Keisuke Kataoka (片岡 圭亮):1, Tetsuichi Yoshizato (吉里 哲一):1, Hideki Makishima (牧島 秀樹):1, Kenichi Yoshida (吉田 健一):1, Seishi Ogawa (小川 誠司):1
1:Department of Pathology and Tumor Biology, Kyoto University, 2:DSK Project, Medical Innovation Center, Kyoto University, 3:Genomic Science Labolatories, Sumitomo Dainippon Pharma Co., Ltd.

Integrated molecular analysis of myelodysplastic syndromes using whole genome sequencing

[演者] Yasuhito Nannya (南谷 泰仁):1
[著者] Kenichi Yoshida (吉田 健一):1, June Takeda (竹田 淳恵):1, Tetsuichi Yoshizato (吉里 哲一):1, Keisuke Kataoka (片岡 圭亮):1, Masahiro Nakagawa (中川 正宏):1, Hideki Makishima (牧島 秀樹):1, Yuichi Shiraishi (白石 友一):2, Kenichi Chiba (千葉 健一):2, Hiroko Tanaka (田中 洋子):2, Tomoki Naoe (直江 知樹):3, Hitoshi Kiyoi (清井 仁):4, Shigeru Chiba (千葉 滋):5, Norio Asou (麻生 範雄):6, Yasushi Miyazaki (宮崎 泰司):7, Satoru Miyano (宮野 悟):2, Seishi Ogawa (小川 誠司):1
1:Pathol. & Tumor Biol., Kyoto Univ., Kyoto, Japan, 2:Lab. of DNA Information Analysis, HGC, Univ. of Tokyo, Tokyo, Japan, 3:Nagoya Medical Center, Nagoya, Japan, 4:Dept. of Hematol. and Oncol., Nagoya Univ., Nagoya, Japan, 5:Dept. of Hematol., Univ. of Tsukuba, Tsukuba, Japan, 6:Saitama Medical Univ. International Medical Center, Saitama, Japan, 7:Dept. of Hematol., Nagasaki Univ., Nagasaki, Japan

A leukemic stem cell signature-based scoring system for prognostication in myelodysplastic syndrome

[演者] Chi-Yuan Yao:1
[著者] Chien-Chin Lin:1, Hsin-An Hou:1, Chein-Jun Kao:1, Mei-Hsuan Tseng:1, Wen-Chien Chou:1, Hwei-Fang Tien:1
1:Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Importance of functional analysis of TERT gene mutations in the diagnosis of dyskeratosis congenita

[演者] Kazuki Terada (寺田 和樹):1,2
[著者] Hiroki Yamaguchi (山口 博樹):1, Koichi Miyake (三宅 弘一):2, Noriko Miyake (三宅 紀子):2, Yoshiki Osaki (大崎 由喜):1, Takashi Okada (岡田 尚巳):2, Seiji Kojima (小島 勢二):3, Etsuro Ito (伊藤 悦朗):4, Koiti Inokuchi (猪口 孝一):1
1:Department of Hematology, Nippon Medical School, Tokyo, Japan, 2:Department of Biochemistry and Molecular Biology, Nippon Medical School, 3:Department of Pediatrics, Nagoya University Graduate School of Medicine, 4:Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki

FANCD2 monoubiquitination for diagnosing Fanconi anemia in the era of high-throughput sequencing

[演者] Nozomu Kawashima (川島 希):1
[著者] Yusuke Okuno (奥野 友介):1, Hideki Muramatsu (村松 秀城):1, Asahito Hama (濱 麻人):1, Atsushi Narita (成田 敦):1, Shinsuke Kataoka (片岡 伸介):1, Motoharu Hamada (濱田 太立):1, Daisuke Ichikawa (市川 大輔):1, Norihiro Murakami (村上 典寛):1, Daiei Kojima (小島 大英):1, Kyogo Suzuki (鈴木 喬悟):1, Eri Nishikawa (西川 英里):1, Nobuhiro Nishio (西尾 信博):1, Yozo Nakazawa (中沢 洋三):2, Seiji Kojima (小島 勢二):1, Yoshiyuki Takahashi (高橋 義行):1
1:Pediatr., Nagoya Univ., Nagoya, Japan, 2:Pediatr., Shinshu Univ., Matsumoto, Japan

Whole exome sequency analysis of congenital dyserythropoietic anemia in Japan

[演者] Motoharu Hamada (濱田 太立):1
[著者] Sayoko Doisaki (土居崎 小夜子):1,2, Yusuke Okuno (奥野 友介):3, Hideki Muramatsu (村松 秀城):1, Asahito Hama (濱 麻人):1, Shinsuke Kataoka (片岡 伸介):1, Daisuke Ichikawa (市川 大輔):1, Rieko Taniguchi (谷口 理恵子):1, Kyogo Suzuki (鈴木 喬悟):1, Daiei Kojima (小島 大英):1, Yuko Sekiya (関谷 由子):1, Nozomu Kawashima (川島 希):1, Atsushi Narita (成田 敦):1, Kenichi Yoshida (吉田 健一):4, Yuichi Shiraishi (白石 友一):5, Masashi Sanada (真田 昌):4,6, Kenichi Chiba (千葉 健一):5, Hiroko Tanaka (田中 洋子):5, Atsushi Manabe (真部 淳):7, Takashi Taga (多賀 崇):8, Yoshiyuki Takahashi (高橋 義行):1, Satoru Miyano (宮野 悟):5,9, Seishi Ogawa (小川 誠司):4, Seiji Kojima (小島 勢二):1
1:Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2:Children's Medical Center, Japanese Red Cross Nagoya First Hospital, 3:Center for Advanced Medicine Clinical Research, Nagoya University Hospital, Japan, 4:Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 5:Laboratory of DNA Information Analysis, Tokyo University, Tokyo, Japan, 6:Department of Advanced Diagnosis, Nagoya Medical Center, Nagoya, Japan, 7:Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan, 8:Department of Pediatrics, Shiga University of Medical Science, Ohtsu, Japan, 9:Laboratory of Sequence Analysis, Tokyo University, Tokyo, Japan

Whole-exome sequencing for genetic diagnosis in patients with hereditary spherocytosis in Taiwan

[演者] Pei-Chin Lin:1,2,10
[著者] Shyh-Shin Chiou:1,2,10, Chien-Yu Lin:3,8,9, His-Yuan Huang:3, Yu-Hsin Tseng:10, Ching-Tien Peng:4,7, Jan-Gowth Chang:3,5,6
1:Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 2:Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 3:Epigenome Research Center, Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan, 4:Department of Hematology-Oncology, Children's Hospital of China Medical University, Taichung, Taiwan, 5:Department of Laboratory Medicine, China Medical University Hospital, Taichung, Taiwan, 6:School of Medicine, China Medical University, Taichung, Taiwan, 7:Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan, 8:Department of Laboratory Medicine, China Medical University Children's Hospital, Taichung, Taiwan, 9:Granduate Institute of Clinical Medical Science and College of Public Health, China Medical University, Taichung, Taiwan, 10:Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Role of insulin-like growth factor-related protein in human erythropoiesis and HbE/beta-thalassemia

[演者] Kasem Kulkeaw:1
[著者] Ayako Yumine-Takai:1, Mei I. Lai:2, Wai Feng Lim:2, Saovaros Svasti:3, Yoichi Nakanishi:4, Daisuke Sugiyama:1
1:Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan, 2:Department of Pathology (Haematology Unit), Faculty of Medicine and Health Science, Universiti Putra Malaysia, Kuala Lumpur, Malaysia, 3:Thalassemia Research Center, Institute of Molecular Biosciences(MB), Mahidol University, Nakhonpathom, Thailand, 4:Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan

Genetic and transcriptional analyses of plasma cells in POEMS syndrome

[演者] Yuhei Nagao (永尾 侑平):1,2
[著者] Naoya Mimura (三村 尚也):1,3, June Takeda (竹田 淳恵):4, Kenichi Yoshida (吉田 健一):4, Yusuke Shiozawa (塩澤 裕介):5, Motohiko Oshima (大島 基彦):6, Kazumasa Aoyama (青山 和正):6, Atsunori Saraya (更屋 敦則):6, Yoshinori Hasegawa (長谷川 嘉則):7, Yuichi Shiraishi (白石 友一):8, Kenichi Chiba (千葉 健一):8, Hiroko Tanaka (田中 洋子):8, Chika Kawajiri-Manako (川尻-真子 千華):1, Nagisa Oshima-Hasegawa (大島-長谷川 渚):1, Shokichi Tsukamoto (塚本 祥吉):1, Shio Sakai (酒井 紫緒):1,3, Yusuke Takeda (竹田 勇輔):1, Chikako Ohwada (大和田 千桂子):1, Masahiro Takeuchi (武内 正博):1, Emiko Sakaida (堺田 惠美子):1, Tohru Iseki (井関 徹):1,3, Sonoko Misawa (三澤 園子):9, Satoru Miyano (宮野 悟):8, Osamu Ohara (小原 收):10, Koutaro Yokote (横手 幸太郎):2, Satoshi Kuwabara (桑原 聡):9, Masashi Sanada (真田 昌):11, Atsushi Iwama (岩間 厚志):6, Seishi Ogawa (小川 誠司):4, Chiaki Nakaseko (中世古 知昭):1,12
1:Department of Hematology, Chiba University Hospital, Chiba, Japan, 2:Department of Clinical Cell Biology and Medicine, Chiba University, 3:Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, 4:Department of Pathology and Tumor Biology, Kyoto University, 5:Department of Pediatrics, The University of Tokyo, 6:Department of Cellular and Molecular Medicine, Chiba University, 7:Department of Research & Development, Kazusa DNA Research Institute, 8:Institute of Medical Science, The University of Tokyo, 9:Department of Neurology, Chiba University, 10:Department of Technology Development, Kazusa DNA Research Institute, 11:Clinical Research Center, National Hospital Organization Nagoya Medical Center, 12:Department of Hematology, International University of Health and Welfare

Cyclin D1 transcript variant in mantle cell lymphoma and myeloma with chromosome 11q13 abnormalities

[演者] Yoshiaki Chinen (知念 良顕):1
[著者] Taku Tsukamoto (塚本 拓):1, Yayoi Kimoto (木元 弥生):1, Tomoko Takimoto (滝本 とも子):1, Yoshimi Mizuno (水野 芳美):1, Saori Maegawa (前川 紗央梨):1, Saeko Ota (大田 沙絵子):1, Kazuna Tanba (丹波 和奈):1, Yuji Shimura (志村 勇司):1, Tsutomu Kobayashi (古林 勉):1, Shigeo Horiike (堀池 重夫):1, Junya Kuroda (黒田 純也):1
1:Div., Hematol., Oncol., Kyoto Prefectural University of Medicine, Kyoto, Japan

Unusual detection of a BRAF G596R mutation in an extraosseous plasmacytoma

[演者] Gabriel C. Caponetti:1
1:Hospital of the University of Pennsylvania, USA

PKA-mediated A3B phosphorylation suppresses genomic instability in MM cells

[演者] Tadahiko Matsumoto (松本 忠彦):1
[著者] Kotaro Shirakawa (白川 康太郎):1, Hirofumi Fukuda (福田 寛文):1, Hiroyuki Matsui (松井 宏行):1, Hiroyuki Yamazaki (山崎 寛章):1, Yasuhiro Kazuma (数馬 安浩):1, Wataru Maruyama (丸山 亙):2, Akifumi Takaori-Kondo (高折-近藤 晃史):1
1:Hematol. and Oncol., Kyoto Univ., Kyoto, Japan, 2:Hematol., Tenri Hospital, Tenri City, Japan

Clinical impact of long non coding RNA MALAT1 expression in multiple myeloma patients

[演者] Hiroshi Handa (半田 寛):1
[著者] Yuko Kuroda (黒田 裕子):2, Kei Kimura (木村 恵):2, Kazuki Honma (本間 和貴):2, Yuta Masuda (増田 裕太):2, Tetsuhiro Kasamatsu (笠松 哲光):2, Nanami Gotoh (後藤 七海):2, Takayuki Saitoh (齋藤 貴之):2, Hirokazu Murakami (村上 博和):2
1:Hematology, Gunma Univ., Maebashi, Japan, 2:Health Science, Gunma Univ., Maebashi, Japan

Novel stem cell-targeted therapy for multiple myeloma based on dual inhibition of EZH1/2

[演者] Makoto Nakagawa (中川 亮):1,2
[著者] Shuhei Fujita (藤田 修平):1, Daisuke Honma (本間 大輔):3, Kazushi Araki (荒木 一司):3, Tatsuya Inoue (井上 竜也):4, Ayako Kato (加藤 亜矢子):4, Koichiro Inaki (稲木 公一郎):4, Chisa Wada (和田 千佐):4, Yoshimasa Ono (小野 祥正):4, Yasuharu Nakashima (中島 康晴):2, Issay Kitabayashi (北林 一生):1
1:Hematological Malignancy, Natl. Cancer Ctr. Res. Inst., Tokyo, Japan, 2:Dept. of Orthop. Surg., Kyushu Univ., Fukuoka, Japan, 3:Oncol. Lab., Daiichi Sankyo, Tokyo, Japan, 4:Disc. Sci. & Tech. Dept., Daiichi Sankyo RD Novare, Tokyo, Japan

HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications

[演者] Takeshi Harada:1
[著者] Hiroto Ohguchi:1, Yohann Grondin:2, Shohei Kikuchi:1, Morihiko Sagawa:1, Yu-Tzu Tai:1, Ralph Mazitschek:3, Teru Hideshima:1, Kenneth C. Anderson:1
1:Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 2:Molecular and Integrative Physiological Sciences Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 3:Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA

Ribonucleotide reductase large subunit (RRM1) as a novel therapeutic target in multiple myeloma

[演者] Morihiko Sagawa (佐川 森彦):1,2
[著者] Hiroto Ohguchi (大口 裕人):1, Takeshi Harada (原田 武志):1, Mehmet K. Samur:3, Yu-Tzu Tai:1, Nikhil C. Munshi:1, Masahiro Kizaki (木崎 昌弘):2, Teru Hideshima (秀島 輝):1, Kenneth C. Anderson:1
1:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 2:Department of Hematology, Saitama Medical Center, Saitama Medical University, 3:Department of Biostatics and Computational Biology, Dana-Farber Cancer Institute, Boston

Immunodulatory drug binding protein TP53RK is a novel therapeutic target in multiple myeloma

[演者] Teru Hideshima:1
[著者] Francesca Cottini:1, Yoshihisa Nozawa:2, Hyuk-Soo Seo:1, Hiroto Ohguchi:1, Mehmet K. Samur:1, Diana Cirstea:1, Naoya Mimura:1, Yoshikazu Iwasawa:2, Paul Richardson:1, Nikhil C. Munshi:1, Dharminder Chauhan:1, Walter Massefski:1, Teruhiro Utsugi:2, Sirano Dhe-Paganon:1, Kenneth C. Anderson:1
1:Dana-Farber Cancer Institute, Harvard Medical School, USA, 2:TAIHO Pharmaceutical Co., Ltd.

Usefulness of presepsin for early detection of infections in patients with hematologic disorders

[演者] Kazutoshi Ebisawa (海老澤 和俊):1
[著者] Junji Koya (古屋 淳史):1, Shunya Arai (荒井 俊也):1, Fumihiko Nakamura (中村 文彦):1, Mineo Kurokawa (黒川 峰夫):1,2
1:Hematology and Oncology, Tokyo Univ., Tokyo, Japan, 2:Cell Therapy and Transplantation Medicine, Tokyo Univ., Tokyo, Japan

Repeat blood cultures during febrile neutropenia in chemotherpy for acute myeloid leukemia

[演者] Shun-Ichi Kimura (木村 俊一):1
[著者] Ayumi Gomyo (後明 晃由美):1, Jin Hayakawa (早川 仁):1, Masaharu Tamaki (玉置 雅治):1, Yu Akahoshi (赤星 佑):1, Naonori Harada (原田 尚憲):1, Tomotaka Ugai (鵜飼 知嵩):1, Machiko Kusuda (楠田 待子):1, Kazuaki Kameda (亀田 和明):1, Hidenori Wada (和田 英則):1, Yuko Ishihara (石原 優子):1, Koji Kawamura (河村 浩二):1, Kana Sakamoto (坂本 佳奈):1, Miki Sato (佐藤 美樹):1, Kiriko Terasako-Saito (齋藤 桐子):1, Misato Kikuchi (菊地 美里):1, Hideki Nakasone (仲宗根 秀樹):1, Shinichi Kako (賀古 真一):1, Yoshinobu Kanda (神田 善伸):1,2
1:Division of Hematology, Saitama Medical Center, Jichi Medical University, 2:Division of Hematology, Department of Medicine, Jichi Medical University

Withdrawn

IFIT1 polymorphism as a genetic marker of cerebral malaria in Thai population

[演者] Pornlada Nuchnoi:1
[著者] Saw Thu Wah:1, Hathairad Hananantachai:2, Jun Ohashi:3, Izumi Naka:3, Jintana Patarapotikul:2
1:Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, 2:The Faculty of Tropical Medicine, Mahidol University, 3:The University of Tokyo, Tokyo, Japan

Assessment of coagulation profile, fibrinogen, PC, PS, AT and vitamin K among Sudanese septic neonates

[演者] Albara Ahmed:1
[著者] Babiker Mohamed:2, Abdulhalim Nasr:3, Awadelkarim Abbas:4
1:Alfajr College for Sciences and Technology, Sudan, 2:Karary University, 3:Omdurman Maternity Hospital, 4:Northern State University

Genomic basis and treatment of Waldenstrom's macroglobulinemia

[演者] Steven P. Treon:1
1:Dana-Farber Cancer Institute, USA

Genetic landscape of primary testicular lymphoma

[演者] Mizuki Watanabe (渡邊 瑞希):1
[著者] Kenichi Yoshida (吉田 健一):1, Yoichi Fujii (藤井 陽一):1, June Takeda (竹田 淳恵):1, Yuichi Shiraishi (白石 友一):2, Yusuke Shiozawa (塩澤 裕介):3, Kenichi Chiba (千葉 健一):2, Ai Okada (岡田 愛):2, Hiroko Tanaka (田中 洋子):2, Go Yamamoto (山本 豪):4, Yasunori Ota (大田 泰徳):5, Satoru Miyano (宮野 悟):2, Koji Izutsu (伊豆津 宏二):4, Seishi Ogawa (小川 誠司):1
1:Pathology and Tumor Biology, Graduate School of Medicine, Kyoto, Japan, 2:Human Genome Center, University of Tokyo, Tokyo, Japan, 3:Pediatrics Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 4:Department of Hematology, Toranomon Hospital, Tokyo, Japan, 5:Department of Pathology, Teikyo University

Assessment index of clinical transformation of follicular lymphoma to diffuse large B-cell lymphoma

[演者] Takafumi Shichijo (七條 敬文):1
[著者] Dai Maruyama (丸山 大):1, Kinuko Tajima (田島 絹子):1, Sayako Yuda (油田 さや子):1, Akiko Maeshima (前島 亜希子):2, Tomotaka Suzuki (鈴木 智貴):1, Kosuke Toyoda (豊田 康祐):1, Nobuhiko Yamauchi (山内 寛彦):1, Shinichi Makita (蒔田 真一):1, Suguru Fukuhara (福原 傑):1, Wataru Munakata (棟方 理):1, Yukio Kobayashi (小林 幸夫):1, Hirokazu Taniguchi (谷口 浩和):2, Kensei Tobinai (飛内 賢正):1
1:Hematology, National Cancer Center Hospital, Tokyo, Japan, 2:Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan

ASXL1 mutation induces MDS with derepression of p16Ink4a via aberrant histone modification by PRC1

[演者] Masahiro Uni (宇仁 暢大):1
[著者] Yosuke Masamoto (正本 庸介):1, Tomohiko Sato (佐藤 智彦):1, Shunya Arai (荒井 俊也):1, Mineo Kurokawa (黒川 峰夫):1
1:The Department of Hematology and Oncology, The University of Tokyo

Generation of induced pluripotent stem cell-derived erythroblasts of X-linked sideroblastic anemia

[演者] Shunsuke Hatta (八田 俊介):1
[著者] Tohru Fujiwara (藤原 亨):1, Takako Yamamoto (山本 貴子):2, Mayumi Kamata (鎌田 真弓):1, Noriko Fukuhara (福原 規子):1, Yasushi Onishi (大西 康):1, Yoshiko Tamai (玉井 佳子):3, Yukio Nakamura (中村 幸夫):4, Shin Kawamata (川真田 伸):2, Hideo Harigae (張替 秀郎):1
1:Dept. Hematol. and Rheumatol., Tohoku Univ., Sendai, Japan, 2:Div. Cell Therapy, Foundation of Biomed. Res. Innovation, Kobe, Japan, 3:Dept. Gastroenterol. and Hematol., Hirosaki Univ., Hirosaki, Japan, 4:Cell Engineering Div., RIKEN BioResource Center, Tsukuba, Japan

演題取り消し

Microenvironment and immunity of peripheral T-cell lymphoma including AILT and ATLL

[演者] Koichi Ohshima (大島 孝一):1
1:Department of Pathology, Kurume University, Japan

Current and future management of NK/T-cell lymphoma

[演者] Motoko Yamaguchi (山口 素子):1
1:Dept. Hematol. Oncol., Mie Univ. Grad. Sch. Med., Tsu, Japan

New horizons in the treatment of Hodgkin lymphoma

[演者] Andreas Engert:1
1:University Hospital of Cologne, Cologne, Germany

Advances in clinical and basic researches in MDS

[演者] Yasuhito Nannya (南谷 泰仁):1
1:Dept. of Pathol. and Tumor Biol., Kyoto Univ., Kyoto, Japan

Spectrum & flowcytometry study in primary MDS

[演者] Hara Prasad Pati:1
1:Dept. of Hematology, All India Institute of Medical Sciences, New Delhi, India

Incidence and characteristics of polycythemia vera, essential thrombocythemia and primary myelofibrosis in Thailand: A patient cohort in the tertiary care hospital

[演者] Noppadol Siritanaratkul:1
[著者] Kamoltip Lertchaisataporn:1, Dusit Jit-ueakul:1, Chalermchai Mitrpant:2, Boonrat Tassaneetrithep:3, Sirikwan Boonmoh:1, Ployploen Phikulsod:1, Archrob Khuhapinant:1
1:Division of Hematology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 2:Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 3:Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

B cell immune profiles in essential thrombocythemia

[演者] Ken-Hong Lim:1,2
1:Division of Hematology and Oncology, MacKay Memorial Hospital, Taipei, Taiwan, 2:Department of Medicine, MacKay Medical College, New Taipei City, Taiwan

Asian CML: How different is it from the West?

[演者] Thuan Heng Charles Chuah:1,2
1:Department of Haematology, Singapore General Hospital, Singapore, 2:Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore

Patient-reported outcomes in patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy in China

[演者] Lanping Xu:1
1:Peking University People's Hospital, Peking University Institute of Hematology, China

The future prospects for treatment free remission in CML

[演者] Dong-Wook Kim:1
1:Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

CNAs and fusion transcripts in pediatric B-ALL cases: Data from a tertiary care hospital of India

[演者] Minu Singh:1
[著者] Prateek Bhatia:1, Amita Trehan:1, Neelam Verma:1, Manupdesh S. Sachdeva:1, Deepak Bansal:1, Rajendra Marathe:1, Richa Jain:1
1:Post Graduate Institute of Medical Education and Research, Chandigarh, India

Can extended maintenance therapy improve BCP-ALL with IKZF1 alteration or iAMP21?

[演者] Keisuke Kato (加藤 啓補):1
[著者] Yuka Iijima-Yamashita (飯島-山下 友加):2, Ai Yoshimi (吉見 愛):1, Satoru Matsushima (松島 悟):1, Chie Kobayashi (小林 千恵):1,3, Kazutoshi Koike (小池 和俊):1, Masahiro Tsuchida (土田 昌宏):1
1:Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, 2:National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 3:Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan

Detecting somatic mutations by next-generation sequencing in childhood LCH

[演者] Ko Kudo (工藤 耕):1
[著者] Tsutomu Toki (土岐 力):1, Tomohiko Sato (佐藤 知彦):1, Akie Kobayashi (小林 明恵):1, Takuya Kamio (神尾 卓哉):1, Shinya Sasaki (佐々木 伸也):1, Kiminori Terui (照井 君典):1, Etsuro Ito (伊藤 悦朗):1
1:Dept. Pediatrics, Hirosaki Univ., Japan

Reduced toxicity-related haploHSCT and prophylactic NK-DLI in pediatric hematologic malignancy

[演者] Keisuke Kato (加藤 啓補):1
[著者] Ai Yoshimi (吉見 愛):1, Takuya Nomura (野村 卓哉):2, Tomohei Nakao (中尾 朋平):3, Satoru Matsushima (松島 悟):1, Chie Kobayashi (小林 千恵):1,3, Tadakazu Yokokawa (横川 忠一):2, Takashi Fukushima (福島 敬):3, Kazutoshi Koike (小池 和俊):1, Masahiro Tsuchida (土田 昌宏):1
1:Divisions of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Japan, 2:Divisions of Medical Engineering, Ibaraki Children's Hospital, Japan, 3:Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan

Ingrown toenails in patients with hematological diseases and solid tumors

[演者] Daiki Hori (堀 大紀):1
[著者] Ryoji Kobayashi (小林 良二):1, Hirozumi Sano (佐野 弘純):1, Daisuke Suzuki (鈴木 大介):1, Kunihiko Kobayashi (小林 邦彦):1
1:Hematology/Oncology for Children/Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan

Prevalence and Implication of XmnI polymorphism and alpha thalassemia in beta thalassemia

[演者] Humaira Yasmeen:1,2,3
[著者] Sarmad Toma:3, Natalie Killeen:3, Shahida Hasnain:2, Foroni Letizia:3
1:Department of Microbiology and Molecular Genetics, The Women University, Multan, Pakistan, 2:Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan, 3:Department of Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom

Withdrawn

Longitudinal follow-up of low bone mineral density after acute lymphoblastic leukemia in Taiwan

[演者] Ting-Chi Yeh:1
[著者] Hsi-Che Liu:1, Jen-Yin Hou:1, Kuan-Hao Chen:1, Ting-Huan Huang:1, Der-Cherng Liang:1
1:Pediatric Hematology/Oncology, MacKay Memorial Hospital, Taipei, Taiwan

Oocyte cryopreservation for a patient with recurrent Burkitt's lymphoma after reaching majority

[演者] Hideto Ogata (緒方 瑛人):1
[著者] Katsutsugu Umeda (梅田 雄嗣):1, Takashi Mikami (三上 貴司):1, Takayuki Hamabata (濱端 隆行):1, Tomoo Daifu (大封 智雄):1, Seishiro Nodomi (納富 誠司郎):1, Itaru Kato (加藤 格):1, Hidefumi Hiramatsu (平松 英文):1, Miyuki Ito (伊藤 美幸):2, Akihito Horie (堀江 昭史):2, Souichi Adachi (足立 壮一):3, Toshio Heike (平家 俊男):1
1:Department of Pediatrics, Kyoto University, Kyoto, Japan, 2:Department of Ginecology and Obstetrics, Kyoto University, Kyoto, Japan, 3:Human Health Sciences, Kyoto University, Kyoto, Japan

Novel therapeutic strategies for multiple myeloma

[演者] Shaji Kumar:1
1:Mayo Clinic, USA

Therapeutic approach for T-cell lymphoma

[演者] Steven M. Horwitz:1
1:Memorial Sloan Kettering Cancer Center, USA

New insights into therapeutic targets in multiple myeloma

[演者] Kenneth C. Anderson:1
1:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Management of Multiple Myeloma: The Changing Paradigm

[Speaker] Shaji K Kumar:1
1:Division of Hematology, Mayo Clinic, Rochester, MN

Treating PTCL: from Multi-drug Regimens to Novel Single Agents

[Speaker] Steven M. Horwitz:1
1:Memorial Sloan Kettering Cancer Center, USA

The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes

[Speaker] Rafael Bejar:1
1:UC San Diego Moores Cancer Center, Division of Hematology and Oncology

Treatment Strategy for Relapsed And Refractory Multiple Myeloma

[Speaker] Henk M. Lokhorst:1
1:Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands

What Japanese Hematologists Need to Know in Chronic Myeloid Leukemia in 2018 -Message from an ELN Expert Panel Member

[Speaker] François-Xavier Mahon:1
1:Institut Bergonié, France

Treatment Strategy for Indolent Lymphoma

[Speaker] Mathias J. Rummel:1
1:The Department for Hematology at the Clinic for Hematology and Medical Oncology at the Justus-Liebig University-Hospital

Molecular mechanisms of leukemia stem cell maintenance by MLL fusion proteins

[演者] Akihiko Yokoyama (横山 明彦):1
[著者] Hiroshi Okuda (奥田 博史):1,2, Boban Stanojevic:2, Satoshi Takahashi (高橋 慧):1,2, Akinori Kanai (金井 昭教):3, Hirotaka Matsui (松井 啓隆):3, Akifumi Takaori-Kondo (高折-近藤 晃史):2
1:Tsuruoka Metabolomics Laboratory, National Cancer Center, Tsuruoka, Japan, 2:Kyoto University Graduate School of Medicine, Kyoto, Japan, 3:Hiroshima Univeristy, Hiroshima, Japan

iPSC model of Shwachman syndrome reveals the apoptotic predisposition of hemoangiogenic progenitors

[演者] Takayuki Hamabata (濱端 隆行):1
[著者] Katsutsugu Umeda (梅田 雄嗣):1, Takayuki Tanaka (田中 孝之):1, Tomoo Daifu (大封 智雄):1, Seishiro Nodomi (納富 誠司郎):1, Satoshi Saida (才田 聡):1, Itaru Kato (加藤 格):1, Shiro Baba (馬場 志郎):1, Hidefumi Hiramatsu (平松 英文):1, Akira Niwa (丹羽 明):2, Megumu K Saito (斎藤 潤):2, Yasuhiko Kamikubo (上久保 靖彦):3, Souichi Adachi (足立 壮一):3, Yoshiko Hashii (橋井 佳子):4, Akira Shimada (嶋田 明):5, Hiroyoshi Watanabe (渡辺 浩良):6, Kenji Osafune (長船 健二):2, Tatsutoshi Nakahata (中畑 龍俊):2, Kenichiro Watanabe (渡邉 健一郎):7, Toshio Heike (平家 俊男):1
1:Pediatrics, Kyoto Univ., Kyoto, Japan, 2:CiRA, Kyoto Univ., Kyoto, Japan, 3:Human Health Sciences, Kyoto Univ., Kyoto, Japan, 4:Pediatrics, Osaka Univ., Suita, Japan, 5:Pediatrics, Okayama Univ., Okayama, Japan, 6:Pediatrics, Faculty of Medicine, Tokushima Univ., Tokushima, Japan, 7:Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan

CD98 turns into a specific target for antibody therapy under severe ER stress in multiple myeloma

[演者] Naoki Hosen (保仙 直毅):1
[著者] Kana Hasegawa (長谷川 加奈):1, Yusuke Oji (尾路 祐介):2, Atsushi Kumanogoh (熊ノ郷 淳):3, Haruo Sugiyama (杉山 治夫):4
1:Cancer Stem Cell Biology, Osaka Univ., Osaka, Japan, 2:Functional Diagnostic Science, Osaka Univ., Osaka, Japan, 3:Respiratory Medicine and Clinical Immunology, Osaka Univ., Osaka, Japan, 4:Cancer Immunology, Osaka Univ., Osaka, Japan

Establishment of the novel prognostic model of DLBCL based on microenvironment signature

[演者] Kohta Miyawaki (宮脇 恒太):1
[著者] Takeshi Sugio (杉尾 健志):1, Koji Kato (加藤 光次):1, Hiroaki Miyoshi (三好 寛明):2, Kensuke Sasaki (佐々木 謙介):1, Takahiro Maeda (前田 高宏):1, Koichi Ohshima (大島 孝一):2, Koichi Akashi (赤司 浩一):1
1:Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 2:Department of Pathology, Kurume University, Kurume, Japan

Identification and visualization of FVIII-producing cells in vivo

[演者] Morisada Hayakawa (早川 盛禎):1
[著者] Asuka Sakata (坂田 飛鳥):2, Noriyoshi Fukushima (福嶋 敬宜):3, Satoshi Nishimura (西村 智):2, Yoichi Sakata (坂田 洋一):2, Tsukasa Ohmori (大森 司):1
1:Department of Biochemistry, Jichi Medical University, Tochigi, Japan, 2:Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan, 3:Department of Pathology, Jichi Medical University, Tochigi, Japan

Specific effect of azacitidine for TP53 (+) MDS

[演者] Yasuhito Nannya (南谷 泰仁):1
[著者] June Takeda (竹田 淳恵):1, Shinya Sato (佐藤 信也):2, Yusuke Shiozawa (塩澤 裕介):1,3, Yuichi Shiraishi (白石 友一):4, Keisuke Kataoka (片岡 圭亮):1, Kenichi Chiba (千葉 健一):4, Hiroko Tanaka (田中 洋子):4, Masashi Sanada (真田 昌):5, Shigeru Chiba (千葉 滋):6, Norio Asou (麻生 範雄):7, Hitoshi Kiyoi (清井 仁):8, Shinji Nakao (中尾 眞二):9, Kazuma Ohyashiki (大屋敷 一馬):10, Yasushi Miyazaki (宮崎 泰司):2, Tomoki Naoe (直江 知樹):5, Hideki Makishima (牧島 秀樹):1, Kenichi Yoshida (吉田 健一):1, Satoru Miyano (宮野 悟):4, Seishi Ogawa (小川 誠司):1
1:Pathol. & Tumor Biol., Kyoto Univ., Kyoto, Japan, 2:Dept. of Hematol., Nagasaki Univ., Nagasaki, Japan, 3:Dept. of Pediatrics, Tokyo Univ., Tokyo, Japan, 4:Lab. of DNA Information Analysis, HGC, Tokyo Univ., Tokyo, Japan, 5:National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 6:Dept. of Hematol., Univ. of Tsukuba, Tsukuba, Japan, 7:Dept. of Hematol., Saitama Medical Univ. IMC, Hidaka, Japan, 8:Dept. of Hematol., Nagoya Univ., Nagoya, Japan, 9:Dept. of Hematol., Kanazawa Univ., Kanazawa, Japan, 10:Dept. of Hematol., Tokyo Medical University, Tokyo, Japan

Modulation of innate immunity as a mechanism of Lenalidomide maintenance for multiple myeloma

[演者] Yusuke Furukawa (古川 雄祐):1
[著者] Yoshiaki Kuroda (黒田 芳明):1, Jiro Kikuchi (菊池 次郎):1
1:Div. Stem Cell Reg., CMM, Jichi Med. Univ., Tochigi, Japan

Clinical application of Daratumumab for myeloma

[演者] Henk M. Lokhorst:1
1:VU University Medical Center, Amsterdam, The Netherlands

Clinical development of CAR-T therapy for multiple myeloma

[演者] Ken Ohmine (大嶺 謙):1,2
[著者] Ryosuke Uchibori (内堀 亮介):2, Keiya Ozawa (小澤 敬也):2,3
1:Div. of Hematology, Dept. of Med., Jichi Medical Univ., Tochigi, Japan, 2:Div. of Immuno.-Gene. and Cell Therapy (Takara Bio), Jichi Medical Univ., Tochigi, Japan, 3:Center for Gene. and Cell Therapy, The Institute of Medical Science, The Univ. of Tokyo, Japan

Basic and clinical research on PD-1/PD-L1 in multiple myeloma

[演者] Hermann Einsele:1
1:Haematology and Oncology, University Hospital Wüerzburg, Germany

Regulation of hematopoietic stem cells by C/EBPβ, a transcription factor required for emergency granulopoiesis

[演者] Hideyo Hirai (平位 秀世):1
1:Transfusion Med. & Cell Therapy, Kyoto Univ., Kyoto, Japan

Innate immune networks as regulators of the hematopoietic niche

[演者] Andres Hidalgo:1,2
1:Fundación CNIC, Madrid, Spain, 2:Institute for Cardiovascular Prevention, Munich, Germany

Functional diversity of various disorder-specific macrophage subtype

[演者] Takashi Satoh (佐藤 荘):1,2
1:Research Institute for Microbial Diseases, Osaka Univ., Osaka, Japan, 2:WPI IFReC, Osaka Univ., Osaka, Japan

Identification of a human progenitor with strict monocyte differentiation potential: A counterpart of mouse cMoPs

[演者] Toshiaki Ohteki (樗木 俊聡):1
1:Biodefense Res., Tokyo Medical and Dental Univ., Tokyo, Japan

Development and functions of resident macrophages

[演者] Frederic Geissmann:1
1:Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Murine CALR mutants homologous to human CALR mutants activate STATs, but do not develop MPNs in vivo

[演者] Kotaro Shide (幣 光太郎):1
[著者] Takuro Kameda (亀田 拓郎):1, Masaaki Sekine (関根 雅明):1, Ayako Kamiunten (上運天 綾子):1, Keiichi Akizuki (秋月 渓一):1, Yuki Tahira (田平 優貴):1, Haruko Shimoda (下田 晴子):1, Tomonori Hidaka (日高 智徳):1, Yoko Kubuki (久冨木 庸子):1, Arata Honda (本多 新):2, Masahito Ikawa (伊川 正人):3, Kazuya Shimoda (下田 和哉):1
1:Department of Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan, 2:Organization for Promotion of Tenure Track, University of Miyazaki, Japan, 3:Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Engagement of mutant calreticulin and MPL in a cellular compartment is required for MPL activation

[演者] Nami Masubuchi (増渕 菜弥):1,2
[著者] Marito Araki (荒木 真理人):3, Erina Hayashi (林 英里奈):1, Yinjie Yang (楊 印杰):1, Misa Imai (今井 美沙):1,4, Yoshihisa Mizukami (水上 喜久):1,5, Yumi Hironaka (弘中 由美):1, Hiraku Takei (竹井 拓):1, Soji Morishita (森下 総司):3, Yoshihiko Kihara (木原 慶彦):1,4, Yoko Edahiro (枝廣 陽子):1, Akimichi Ohsaka (大坂 顯通):3, Norio Komatsu (小松 則夫):1
1:Dept. Hemat., Juntendo Univ., Tokyo, Japan, 2:Res. Ins. Dis. Old Age., Juntendo Univ., Tokyo, Japan, 3:Dept. Transfus. Med. & Stem Cell Reg., Juntendo Univ., Tokyo, Japan, 4:Lead. Cent. Dev. Res. Cencer Med., Juntendo Univ., Tokyo, Japan, 5:Cent. Genom. Regen. Med., Juntendo Univ., Tokyo, Japan

MPL activation directly induces fibrocyte differentiation to cause myelofibrosis

[演者] Takaaki Maekawa (前川 隆彰):1
[著者] Yukiko Osawa (大澤 有紀子):1, Takuya Izumi (和泉 拓野):1, Shigeki Nagao (長尾 茂輝):1, Kosuke Takano (高野 昂佑):1, Yosuke Okada (岡田 陽介):1, Noriaki Tachi (田地 規朗):1, Masahiro Teramoto (寺本 昌弘):1, Toshikuni Kawamura (河村 俊邦):1, Toshikatsu Horiuchi (堀内 俊克):1, Reina Saga (嵯峨 玲奈):1, Shoichiro Kato (加藤 章一郎):1, Takeshi Yamamura (山村 武史):1, Junichi Watanabe (渡邉 純一):1, Ayako Kobayashi (小林 彩香):1, Shinichi Kobayashi (小林 真一):1, Ken Sato (佐藤 謙):1, Michihiro Hashimoto (橋本 倫拓):2, Shinya Suzu (鈴 伸也):2, Fumihiko Kimura (木村 文彦):1
1:Hematol., Intern. Med., NDMC, Tokorozawa, Japan, 2:Center for AIDS Research, Kumamoto Univ., Kumamoto, Japan

Deubiquitinase inhibitor WP1130 blocks JAK2-V617F to induce apoptosis in leukemic cells

[演者] Hiroki Akiyama (秋山 弘樹):1
[著者] Yoshihiro Umezawa (梅澤 佳央):1, Keigo Okada (岡田 啓五):1, Shinya Ishida (石田 信也):1, Ayako Nogami (野上 彩子):1, Toshikage Nagao (長尾 俊景):1, Osamu Miura (三浦 修):1
1:Hematology Dept., Tokyo Med. and Dent. Univ., Tokyo, Japan

Clonal analysis of acute myeloid leukemia transformed from myeloproliferative neoplasms

[演者] Yoko Ushijima (牛島 洋子):1
[著者] Yuichi Ishikawa (石川 裕一):2, Hikaru Hattori (服部 光):2, Naomi Kawashima (川島 直実):2, Shun Fujiwara (藤原 峻):3, Seitaro Terakura (寺倉 精太郎):2, Masashi Sanada (真田 昌):3, Hitoshi Kiyoi (清井 仁):2
1:Dept. Hematol., Nagoya Univ. Hosp., Nagoya, Japan, 2:Dept. Hematol. and Oncol., Nagoya Univ., Nagoya, Japan, 3:Clinical Research Center, Nagoya Medical Center, Nagoya, Japan

Genomic basis and treatment of Waldenstrom's macroglobulinemia

[演者] Steven P. Treon:1
1:Dana-Farber Cancer Institute, USA

Contribution of MIR9 on disease progression of chronic myelogenous leukemia

[演者] Ko Sasaki (佐々木 光):1
[著者] Fusako Nagasawa (永澤 英子):1, Kenichi Yoshida (吉田 健一):2, June Takeda (竹田 淳恵):2, Yuichi Shiraishi (白石 友一):3, Kenichi Chiba (千葉 健一):3, Hiroko Tanaka (田中 洋子):3, Ai Okada (岡田 愛):3, Satoru Miyano (宮野 悟):3, Motoshi Ichikawa (市川 幹):1, Seishi Ogawa (小川 誠司):2, Kinuko Mitani (三谷 絹子):1
1:Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan, 2:Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 3:Laboratory of DNA Information Analysis, IMSUT, Tokyo, Japan

Dynamic development of CMV-associated NK cells in Ph⁺ leukemia patients treated with dasatinib

[演者] Kenichi Ishiyama (石山 賢一):1
[著者] Toshio Kitawaki (北脇 年雄):1, Naoshi Sugimoto (杉本 直志):1,2, Akifumi Takaori-Kondo (高折-近藤 晃史):1, Norimitsu Kadowaki (門脇 則光):3
1:Dept. Hematol./Oncol., Kyoto Univ., Kyoto, Japan, 2:Department of Clinical Application, CiRA, Kyoto University, Kyoto, Japan, 3:Division of Hematology, Kagawa University, Kagawa, Japan

BCR-ABL induces expression of an apoptosis inhibitor Survivin via activation of YAP

[演者] Kenta Moriyama (森山 健太):1
[著者] Konomi Maeda (前田 木実):1, Haruka Oshima (大島 遥香):1, Ryotaro Nishi (西 良太郎):1, Toshiyuki Hori (堀 利行):1
1:Biomedical Sci., Ritsumeikan Univ., Kusatsu, Japan

Enhanced perforin expression associated with dasatinib-induced activation of STATs in NK cells

[演者] Noriyoshi Iriyama (入山 規良):1
[著者] Hiromichi Takahashi (高橋 宏通):1, Katsuhiro Miura (三浦 勝浩):1, Yoshihito Uchino (内野 慶人):1, Masaru Nakagawa (中川 優):1, Yoshihiro Hatta (八田 善弘):1, Masami Takei (武井 正美):1
1:Hematol. Rheumatol., Nihon Univ., Tokyo, Japan

RUNX1 and PHF6 mutations in B lymphoblastic blast phase of CML

[演者] Gabriel C. Caponetti:1
1:Hospital of the University of Pennsylvania, USA

Establishment of a megakaryoblastic cell line to conventionally assess platelet calcium signaling

[演者] Hiroshi Saito (齊藤 洋):1
[著者] Atsushi Yasumoto (安本 篤):2, Yutaka Yatomi (矢冨 裕):2, Tsukasa Ohmori (大森 司):1
1:Department of Biochemistry, Jichi Medical Univ., Shimotsuke, Japan, 2:Department of Clinical Laboratory Medicine, Tokyo Univ., Tokyo, Japan

αIIbβ3 activation kinetics reveals distinctive roles of critical molecules in inside-out signaling

[演者] Hisashi Kato (加藤 恒):1
[著者] Hirokazu Kashiwagi (柏木 浩和):1, Yoichiro Morikawa (森川 陽一郎):1, Keigo Akuta (芥田 敬吾):1, Nobuko Nishiura (西浦 伸子):1, Shigenori Honda (本田 繁則):2, Koichi Kokame (小亀 浩市):2, Toshiyuki Miyata (宮田 敏行):2, Yuzuru Kanakura (金倉 譲):1, Yoshiaki Tomiyama (冨山 佳昭):3
1:Hematology and Oncology, Osaka Univ., Osaka, Japan, 2:Molecular Pathogenesis, National Cerebral and Cardiovascular Center, 3:Blood Transfusion, Osaka University Hospital

Functional analysis of the fibrinolytic system in the pathogenesis of Hemophagocytic syndrome

[演者] Hiroshi Shimazu (島津 浩):1,2
[著者] Shinya Munakata (宗像 慎也):2, Yoshihiko Tashiro (田代 良彦):2, Tsuyoshi Takahashi (高橋 強志):1, Hiromitsu Nakauchi (中内 啓光):2, Beate Heissig:2, Koichi Hattori (服部 浩一):2
1:Mitsui Memorial Hospital, Tokyo, Japan, 2:Div. Stem Cell Therapy, IMSUT, Tokyo, Japan

Peripheral eosinophilic mobilization and activation correlated with coronary arterial thrombogenesis

[演者] Qu Cui:1
[著者] Yuedan Chen:1, Jie Huo:2, Dezhao Wang:3, Masahiro Abe:4
1:Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, China, 2:Department of Emergency, Beijing Tiantan Hospital, Capital Medical University, 3:Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, 4:Department of Haematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan

A prospective evaluation of molecular markers of the new JSTH criteria in sepsis-induced DIC

[演者] Seiji Madoiwa (窓岩 清治):1
[著者] Hitomi Satoh (佐藤 瞳):2, Yuko Kondoh (近藤 裕子):2, Hiroko Takeda (武田 裕子):2, Junko Nozaki (野崎 順子):3, Masahide Kawamura (川村 雅英):3, Shinsuke Funakoshi (船越 信介):4, Maki Hirao (平尾 磨樹):5, Yuiko Tsukada (塚田 唯子):5, Takahide Kikuchi (菊池 隆秀):5, Kentaro Watanabe (渡辺 健太郎):5, Ken-Ichiro Sasao (笹尾 健一郎):6, Kazuhiko Sekine (関根 和彦):6
1:Clinical Laboratory Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan, 2:Clinical Laboratory, Tokyo Saiseikai Central Hospital, 3:LSI Medience, 4:Medical Oncology, Tokyo Saiseikai Central Hospital, 5:Hematology, Tokyo Saiseikai Central Hospital, 6:Emergency and Critical Care Medicine, Tokyo Saiseikai Central Hospital

MDS stem cell behavior: Can it predict clinical outcomes?

[演者] Stephen D. Nimer:1
1:Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, USA

Intensive remission induction therapy for hepatosplenic T-cell lymphoma and long complete remission

[演者] Takeshi Okatani (岡谷 健史):1
[著者] Hideki Asaoku (麻奥 英毅):1, Ryota Imanaka (今中 亮太):1, Kohei Kyo (許 鴻平):1, Mitsuhiro Itagaki (板垣 充弘):1, Yuta Katayama (片山 雄太):1, Shinya Katsutani (勝谷 慎也):1, Koji Iwato (岩戸 康治):2, Megumu Fujiwara (藤原 恵):3, Taiichi Kyo (許 泰一):4
1:Dev. Hematology, Hiroshima Red Cross Hosp. & Atomic-Bomb Survivors Hosp., Japan, 2:Dev. Transfusion, Hiroshima Red Cross Hosp. & Atomic-Bomb Survivors Hosp., Japan, 3:Dev. Pathology, Hiroshima Red Cross Hosp. & Atomic-Bomb Survivors Hosp., Japan, 4:Dev. Hematology, Itsukaichi Memorial Hosp., Hiroshima, Japan

Mediastinal lesions across the age spectrum: A comparison between pediatric and adult patients

[演者] Lika'a Fasih Y. Al-Kzayer:1
[著者] Tingting Liu:2, Xiao Xie:3, Hua Fan:4, Shamil Naji Sarsam:5, Yozo Nakazawa:1, Lei Chen:6
1:Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Nagano, Japan, 2:Department of Pediatric Hematology-Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 3:Department of Thoracic Cardiovascular Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 4:Department of Radiology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 5:Department of Radiology, Ibn Al-Nafees Hospital, Manama, Kingdom of Bahrain, 6:Department of Pathology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

演題取り下げ

Prognostic significance of CD11b⁺CX3CR1⁺ monocytes in newly diagnosed diffuse large B-cell lymphoma

[演者] Jae-Yong Kwak:1
[著者] Jeong-A Kim:2, Ho-Young Yhim:1, Sun-Hye Ko:2, Youngrok Park:3, Eun Jung Yim:2, Hee Sun Kim:4
1:Department of Internal Medicine, Chonbuk National University Medical School, Korea, 2:Devision of Hematology, Department of Internal Medicine, Catholic University of Korea, Seoul, Republic of Korea, 3:McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA, 4:College of Nursing, Chonbuk National University, Jeonju, Republic of Korea

Diffuse pneumonitis caused by the combined use of the anti-CD20 antibody Obinutuzumab and radiation

[演者] John R. Pawloski:1
[著者] Harry S. Latham:2
1:Cancer Treatment Centers of America-Southeastern Regional Medical Center, USA, 2:Georgia Cell and Tissue Diagnostic Center, Inc.

Intrapleural rituximab for the treatment of malignant pleural effusion due to CD20+ B-cell lymphomas

[演者] Man Fai Law:1
[著者] Hay Nun Chan:2, Ho Kei Lai:2, Chung Yin Ha:2, Celia Ng:2, Yiu Ming Yeung:2, Sze Fai Yip:2
1:Department of Medicine, Prince of Wales Hospital, Hong Kong, 2:Department of Medicine, Tuen Mun Hospital

Effectiveness of single-dose rasburicase in lymphoma patients a high risk for tumor lysis syndrome

[演者] Seok-Goo Cho:1
[著者] Young-Woo Jeon:1, Dae-Hun Kwak:1, Sung-Soo Park:1, Jae-Ho Yoon:1, Sung-Eun Lee:1, Ki-Seong Eom:1, Yoo-Jin Kim:1, Seok Lee:1, Hee-Je Kim:1, Chang-Ki Min:1, Jong Wook Lee:1, Woo-Sung Min:1
1:Hematology, Catholic Unv., Seoul, Korea

The spectrum of anemia in therapy-naive patients with lymphoma and myeloma from North India

[演者] Gaurav Prakash:1
[著者] Durlabhesh Rawat:1, Prashant Sharma:1, Savita Verma:1, Neelam Varma:1, Subhash Varma:1
1:PGIMER, Chandigarh, India

Platelet count and chemotherapy course are factors for success autologous stem cell harvest in NHL

[演者] Hui-Hua Hsiao:1,2,3
[著者] Shih-Hao Tang:1, Ming-Hui Lin:1, Jeng-Shiun Du:1, Hui-Ching Wang:1,2, Yu-Fen Tsai:1,2, Shih-Feng Cho:1,2, Chiung-Tang Huang:1, Jui-Feng Hsu:1, Yi-Chang Liu:1,2, Sheng-Fung Lin:1,2, Ta-Chih Liu:1,2,3
1:Department of Internal Medicine, Kaohsiung Medical Univeristy Hospital, Kaohsiung, Taiwan, 2:Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, 3:Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung

Peripheral blood stem cell transplant in aplastic anemia

[演者] Pravas Mishra:1
[著者] Manoranjan Mahapatra:1, Tulika Seth:1
1:AIIMS, New Delhi, India

300 cGY total body irradiation with fludarabine based conditioning regimen in hematologic malignancy

[演者] Jeong-A Kim:1,2
[著者] Young Hoon Park:1, Eun Jung Yim:1, Jae-Yong Kwak:2
1:Division of Hematology, Department of Internal Medicine, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea, 2:Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Republic of Korea

Toward Investigator-sponsored IND of allogeneic umbilical cord-derived MSC for severe acute GVHD

[演者] Tokiko Nagamura-Inoue (長村 登紀子):1
[著者] Yuka Mori (森 有加):1, Atsuko Takahashi (高橋 敦子):1, Takahisa Shimazu (島津 貴久):1, Takeo Mukai (向井 丈雄):1,2, Fumitaka Nagamura (長村 文孝):2, Arinobu Tojo (東條 有伸):3
1:Cell Processing and Transfusion, IMSUT, 2:Advanced Medical Promotion, IMSUT, 3:Molecular Medicine, IMSUT

Low-dose ruxolitinib for steroid refractory graft-versus-host disease: Report of two cases

[演者] Yasushi Onishi (大西 康):1
[著者] Masahiro Kobayashi (小林 匡洋):1, Satoshi Ichikawa (市川 聡):1, Mai Watanabe (渡邉 真威):1, Kentaro Nasu (那須 健太郎):1, Yoko Okitsu (沖津 庸子):1, Noriko Fukuhara (福原 規子):1, Tohru Fujiwara (藤原 亨):1, Minami Fujiwara (藤原 実名美):1, Hideo Harigae (張替 秀郎):1
1:Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan

Extracorporeal photopheresis with TC-V in Japanese chronic Graft-vs-Host Disease (GVHD) Patients

[演者] Shinichiro Okamoto:1
[著者] Takanori Teshima:2, Koichi Miyamura:3
1:Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan, 2:Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan, 3:Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya Japan

CMV Reactivation improves HSCT outcome in AML patients with matched HLA-C

[演者] Ting-An Lin:1
[著者] Yao-Chung Liu:1,2, Jyh-Pyng Gau:1,2, Liang-Tsai Hsiao:1,2, Chia-Jen Liu:1,2,3, Jin-Hwang Liu:1,2
1:Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2:School of Medicine, National Yang-Ming University, Taipei, Taiwan, 3:Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University, Taipei, Taiwan

Cytomegalovirus infection in children after allogeneic hematopoietic stem cell transplantation

[演者] Tang-Her Jaing:1
[著者] Shih-Hsiang Chen:1, Tsung-Yen Chang:1, Yu-Chuan Wen:2, Chao-Ping Yang:1
1:Department of Pediatric Hematology/Oncology, Chang Gung Children's Hospital, Taoyuan, Taiwan, 2:Department of Nursing, Chang Gung Children's Hospital, Taoyuan, Taiwan

Clinical manifestation and red blood parameters in children with homozygous constant spring disease

[演者] Kamon Phuakpet:1
[著者] Jutipong Boonmuang:1, Kleebsabai Sanpakit:1, Nassawee Vathana:1, Jassada Buaboonnam:1, Nattee Narkbunnam:1, Vip Viprakasit:1
1:Division of Hematology/Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Genetic determinants predict clinical efficacy of hydroxyurea in thalassemia patients

[演者] Surakarn Jansutjawan:1
[著者] Vip Viprakasit:1
1:Division of Hematology & Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Prevalence of thalassemia in infant 6-12 month-old at well baby clinic

[演者] Phakatip Sinlapamongkolkul:1
[著者] Pacharapan Surapolchai:1, Vip Viprakasit:2
1:Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, Thailand, 2:Department of Pediatrics and Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

Prevalence of Iron deficiency in infant 6-12 month-old at well baby clinic

[演者] Pacharapan Surapolchai:1
[著者] Phakatip Sinlapamongkolkul:1, Patcharapa Thaweekul:1, Vip Viprakasit:2
1:Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, Thailand, 2:Department of Pediatrics and Thalassemia Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

20 year old man with hemolytic anemia proved as pyruvate kinase deficiency: Case report

[演者] Jung-A Kim:1
[著者] Hyeran Lee:2
1:Division of Hematology-Oncology, Department of Internal Medicine, Inje University Seoul Paik Hospital, Korea, 2:Division of Hematology-Oncology, Department of Internal Medicine, Inje University Ilsan Paik Hospital

Clinical characteristics and outcome of patients with Kasabach Merrit Syndrome and vascular tumors

[演者] Jassada Buaboonnam:1
[著者] Lilada Anuntarumporn:1, Rattanavalai Nitiyarom:1
1:Department of Pediatrics, Siriraj Hospital Mahidol University, Bangkok, Thailand

Analysis of vulnerability on survival in very elderly patients with multiple myeloma over 75 years

[演者] Kentaro Narita (成田 健太郎):1
[著者] Yoshiaki Abe (安部 佳亮):1, Hiroki Kobayashi (小林 宏紀):1, Masami Takeuchi (竹内 正美):1, Kosei Matsue (末永 孝生):1
1:Hematology/Oncology, Kameda Medical Center, Chiba, Japan

Autologous transplantation in multiple myeloma: North Estonia Medical Centre 10 years experience

[演者] Edward Laane:1
1:North Estonia Medical Centre, Tallinn, Estonia

Exploration the risk and outcome of hemodialysis in multiple myeloma: A nationwide study

[演者] Jia-Hong Chen:1
1:Tri-Service General Hospital, National Defense Medical Center, Taiwan

Rate and pattern of infections among multiple myeloma patients who received induction chemotherapy

[演者] Nor Rafeah Tumian:1
[著者] Zuliana Jamli:1, Petrick Periyasamy:1, Syed Zulkifli Syed Zakaria:1
1:Haematology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Kuala Lumpur, Malaysia

Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed MM patients

[演者] Yao-Chung Liu:1,2
[著者] Yi-Lun Chen:2,3, Chia-Hung Wu:2,4, Chiu-Mei Yeh:2, Hsun-I Chiu:2,3, Gin-Yi Lee:3, Jyh-Pyng Gau:1,2, Liang-Tsai Hsiao:1,2, Tzeon-Jye Chiou:2,7, Jin-Hwang Liu:1,2,5,6, Chia-Jen Liu:1,2
1:Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2:School of Medicine, National Yang-Ming University, Taipei, Taiwan, 3:Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan, 4:Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, 5:Institute of Biopharmaceutical Science, National Yang-Min University, Taipei, Taiwan, 6:Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Min University, Taipei, Taiwan, 7:Division of Transfusion Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

The change of survival rate in patients with multiple myeloma according to the year of diagnosis

[演者] Mai Watanabe (渡邉 真威):1
[著者] Hisayuki Yokoyama (横山 寿行):1, Yuna Katsuoka (勝岡 優奈):1, Mitsue Inomata (猪股 美津恵):1, Toshihiro Ito (伊藤 俊広):1, Kuniaki Meguro (目黒 邦昭):1
1:Department of Hematology, Sendai Medical Center, National Hospital Organization

Frailty score-based treatment strategy for transplant-ineligible elderly myeloma patients

[演者] Kyoko Yoshihara (吉原 享子):1
[著者] Satoshi Yoshihara (吉原 哲):1, Junko Ikemoto (池本 純子):1, Masaya Okada (岡田 昌也):1, Kenichi Yamahara (山原 研一):1, Toshihiro Soma (相馬 俊裕):1, Yoshihiro Fujimori (藤盛 好啓):1
1:Transfusion-Medicine and Cellular-Therapy, Hyogo College of Medicine, Hyogo, Japan

Dose reduced Pomalidomide use may negatively impact on the efficacy for frail double-refractory MM

[演者] Naoya Mochizuki (望月 直矢):1
[著者] Kentaro Mizuhara (水原 健太郎):1, Yuki Fujiwara (藤原 悠紀):1, Shiro Kubonishi (久保西 四郎):1, Yasushi Hiramatsu (平松 靖史):1
1:Hematology/Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan

Cyclin D1 transcript variant in mantle cell lymphoma and myeloma with chromosome 11q13 abnormalities

[演者] Yoshiaki Chinen (知念 良顕):1
[著者] Taku Tsukamoto (塚本 拓):1, Yayoi Kimoto (木元 弥生):1, Tomoko Takimoto (滝本 とも子):1, Yoshimi Mizuno (水野 芳美):1, Saori Maegawa (前川 紗央梨):1, Saeko Ota (大田 沙絵子):1, Kazuna Tanba (丹波 和奈):1, Yuji Shimura (志村 勇司):1, Tsutomu Kobayashi (古林 勉):1, Shigeo Horiike (堀池 重夫):1, Junya Kuroda (黒田 純也):1
1:Div., Hematol., Oncol., Kyoto Prefectural University of Medicine, Kyoto, Japan

Potent anti-tumor effect of combination therapy using AKT inhibitor and pomalidomide with DEX in MM

[演者] Shiori Kinoshita (木下 史緒理):1
[著者] Masaki Ri (李 政樹):1, Takashi Yoshida (吉田 嵩):1, Tomoko Narita (成田 朋子):1, Haruhito Totani (戸谷 治仁):1, Ashour Reham:1,2, Asahi Ito (伊藤 旭):1, Shigeru Kusumoto (楠本 茂):1, Takashi Ishida (石田 高司):1, Hirokazu Komatsu (小松 弘和):1, Shinsuke Iida (飯田 真介):1
1:Department of Hematology and Oncology, Nagoya City Univ., Nagoya, Japan, 2:Clinical Pathology, Qena University Hospital, South Valley University, Qena, Egypt

RUNX2 super enhancer promotes the development of blastic plasmacytoid dendritic cell neoplasm

[演者] Sho Kubota (久保田 翔):1
[著者] Kenji Tokunaga (徳永 賢治):2, Motohiko Oshima (大島 基彦):3, Tomohiro Umezu (梅津 知宏):4, Akinori Kanai (金井 昭教):5, Kar Ton Tan:6, Henry Yang:6, Eisaku Iwanaga (岩永 栄作):2, Norio Asou (麻生 範雄):7, Takahiro Maeda (前田 隆浩):8, Atsushi Iwama (岩間 厚志):3, Kazuma Ohyashiki (大屋敷 一馬):4, Motomi Osato (大里 元美):1,6, Goro Sashida (指田 吾郎):1
1:International Research Center for Medical Sciences, Kumamoto University, 2:Department of Hematology, Kumamoto University, 3:Department of Cellular and Molecular Medicine, Chiba University, 4:Department of Hematology, Tokyo Medical University, 5:Research Institute of Radiation Biology and Medicine, Hiroshima University, 6:Cancer Science Institute of Singapore, National University of Singapore, 7:Dept. Hematology, International Med. Center, Saitama Med. Univ., 8:Department of Community Medicine, Nagasaki University

Non-functional BCR-ABL contributes to fluctuating MRD in CML patients after cessation of TKI therapy

[演者] Junichiro Yuda (湯田 淳一朗):1
[著者] Toshihiro Miyamoto (宮本 敏浩):1, Jun Odawara (小田原 淳):1, Mariko Minami (南 満理子):1, Yasuyuki Ohkawa (大川 恭行):2, Koichi Akashi (赤司 浩一):1
1:Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 2:Department of Advanced Medical Initiatives, Kyushu University, Fukuoka, Japan

Long-term efficacy and safety of Ibrutinib in CLL/SLL patients

[Speaker] Peter Hillmen:1
1:Experimental Haematology University of Leeds

Management of Relapsed/Refractory Multiple Myeloma ～Optimal use of Carfilzomib～

[Speaker] Hermann Einsele:1
1:University Hospital Wuerzburg, Department of Internal Medicine II

TET dioxygenase activity in the development of acute myeloid leukemia

[演者] Shigeru Chiba (千葉 滋):1
1:Hematol., Univ. Tsukuba, Tsukuba, Japan

Targeting epigenetic mechanisms to reverse leukemia stem cell gene expression

[演者] Scott A. Armstrong:1
1:Dana Farber Cancer Institute, Boston, MA, USA

Functional role of DNMT3A mutation in acute myeloid leukemia

[演者] Junji Koya (古屋 淳史):1
[著者] Takashi Higo (比護 貴史):1, Mineo Kurokawa (黒川 峰夫):1,2
1:Department of Hematology and Oncology, The University of Tokyo Hospital, Tokyo, Japan, 2:Department of Cell Therapy and Transplantation, The University of Tokyo Hospital, Tokyo, Japan

Leukemia stem cells play a central role in therapy failure and disease recurrence in human AML

[演者] John E. Dick:1
1:Princess Margaret Cancer Centre and University of Toronto, Canada

Targeting hematopoietic cell kinase with imatinib has therapeutic potential for NK/T cell neoplasms

[演者] Luis Espinoza:1
[著者] Ken Ishiyama:1, Kenichi Harada:1, Takeshi Yoroidaka:1, Ly Trung:1, Shinji Nakao:1
1:Hematol., Kanazawa University, Japan

Early progression of disease in patients with newly diagnosed localized ENKL treated with RT-DeVIC

[演者] Ritsuro Suzuki (鈴木 律朗):1
[著者] Motoko Yamaguchi (山口 素子):2, Masahiko Oguchi (小口 正彦):3, Naoko Asano (浅野 直子):5, Kana Miyazaki (宮崎 香奈):2, Kyoko Ueda (上田 響子):4, Nobuko Kubota (久保田 靖子):6, Takeshi Maeda (前田 猛):7, Yukio Kobayashi (小林 幸夫):8, Jun Amaki (天木 惇):9, Tohru Murayama (村山 徹):10, Bungo Saito (齋藤 文護):11, Emiko Shimoda (下田 絵美子):12, Noriko Fukuhara (福原 規子):13, Norifumi Tsukamoto (塚本 憲史):14, Kazuyuki Shimada (島田 和之):15, Naokuni Uike (鵜池 直邦):16, Takahiko Utsumi (内海 貴彦):17, Naoyuki Katayama (片山 直之):2
1:Oncol. Hematol., Shimane Univ., Izumo, Japan, 2:Hematol. Oncol., Mie Univ., Tsu, Japan, 3:Radiation Oncol., Cancer Institute Hospital, Tokyo, Japan, 4:Hematol. Oncol., Cancer Institute Hospital, Tokyo, Japan, 5:Mol. Diagn., Nagano Prefectural Suzaka Hospital, Suzaka, Japan, 6:Hematol., Saitama Cancer Center, Ina, Japan, 7:Hematol. Oncol., Kurashiki Central Hospital, Kurashiki, Japan, 8:Hematol., National Cancer Center Hospital, Tokyo, Japan, 9:Hematol. Oncol., Tokai University, Isehara, Japan, 10:Hematol., Hyogo Cancer Center, Akashi, Japan, 11:Hematol., Showa University, Tokyo, Japan, 12:Radiation Oncol., Nara Medical University, Kashihara, Japan, 13:Hematol. Rheumatol., Tohoku University, Sendai, Japan, 14:Cancer Center, Gunma University, Maebashi, Japan, 15:Hematol., Nagoya University, Nagoya, Japan, 16:Hematol., Kyushu Cancer Center, Fukuoka, Japan, 17:Hematol. Oncol., Shiga Medical Center, Moriyama, Japan

Phase II multi-center trial of dose-adjusted EPOCH therapy for untreated peripheral T-cell lymphoma

[演者] Isao Yoshida (吉田 功):1
[著者] Yoshinobu Maeda (前田 嘉信):2, Hisakazu Nishimori (西森 久和):2, Yasushi Hiramatsu (平松 靖史):3, Masatoshi Uno (海野 正俊):4, Yasufumi Masaki (正木 康史):5, Kazutaka Sunami (角南 一貴):6, Taro Masunari (増成 太郎):7, Yuichiro Nawa (名和 由一郎):8, Hiromichi Yamane (山根 弘路):9, Hiroshi Gomyo (五明 広志):10, Tsutomu Takahashi (高橋 勉):11, Tomofumi Yano (矢野 朋文):12, Keitaro Matsuo (松尾 恵太郎):13, Koichi Ohshima (大島 孝一):14, Shigeo Nakamura (中村 栄男):15, Tadashi Yoshino (吉野 正):16, Mitsune Tanimoto (谷本 光音):2
1:Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, 2:Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan, 3:Hematology/Oncology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan, 4:Department of Internal Medicine, Kaneda Hospital, Maniwa, Japan, 5:Department of Hematology and Immunology, Kanazawa Medical University, Kahoku-gun, Japan, 6:Department of Hematology, NHO Okayama Medical Center, Okayama, Japan, 7:Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan, 8:Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama, Japan, 9:Department of General Internal Medicine-IV, Kawasaki Medical School, Okayama, Japan, 10:Department of Hematology, Hyogo Cancer Center, Akashi, Japan, 11:Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan, 12:Department of Hematology, Okayama Rosai Hospital, Okayama, Japan, 13:Molecular and Clinical Epidemiology, Aichi Cancer Center, Nagoya, Japan, 14:Department of Pathology, School of Medicine, Kurume University, Kurume, Japan, 15:Department of Pathology, Nagoya University Hospital, Nagoya, Japan, 16:Department of Pathology, Okayama University, Okayama, Japan

Protective effects of KIR-2DS1, KIR-2DS5 and KIR-2DL5 on EBV-related iatrogenic lymphoma (IA-LPD)

[演者] Mai Anh Nguyen Thi:1,2
[著者] Viet Hoang Nguyen:1, Mahmoud I. Elbadry:1,3, Takeshi Yoroidaka:1, Tatsuya Imi:1, Go Aoki:1, Ken Ishiyama:1, Shinji Nakao:1
1:Hematology Department, Kanazawa University, Ishikawa, Japan, 2:Pediatric Department, Faculty of Medicine, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam, 3:Hematology Division, Department of Internal Medicine, Faculty of Medicine, Sohag University Hospital, Sohag, Egypt

TCL-001: A phase I/II Japanese study of romidepsin in relapsed/refractory peripheral T-cell lymphoma

[演者] Masafumi Taniwaki:1
[著者] Dai Maruyama:2, Kensei Tobinai:2, Michinori Ogura:3,4, Kiyohiko Hatake:5, Toshiki Uchida:4, Kiyoshi Ando:6, Kunihiro Tsukasaki:7, Takashi Ishida:8, Naoki Kobayashi:9, Kenichi Ishizawa:10,11, Yoichi Tatsumi:12, Koji Kato:13, Toru Kiguchi:14, Takayuki Ikezoe:15,16, Eric Laille:17, Tokihiro Ro:18, Hiromi Tamakoshi:18, Sanae Sakurai:18, Tomoko Ohtsu:18
1:Department of Hematology and Center for Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2:Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 3:Department of Hematology, Tokai Central Hospital, Gifu, Japan, 4:Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Aichi, Japan, 5:Department of Hematology and Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 6:Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan, 7:Department of Hematology, National Cancer Center Hospital East, Chiba, Japan, 8:Department of Hematology and Oncology, Nagoya City University Hospital, Aichi, Japan, 9:Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan, 10:Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan (present), 11:Department of Hematology and Rheumatology, Tohoku University Hospital, Miyagi, Japan (previous), 12:Department of Hematology & Rheumatology, Kinki University Hospital, Faculty of Medicine, Osaka, Japan, 13:Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan, 14:Department of Hematology, Chugoku Central Hospital, Hiroshima, Japan, 15:Department of Hematology & Respiratory Medicine, Kochi Medical School Hospital, Kochi, Japan (previous), 16:Department of Hematology, Fukushima Medical University School of Medicine, Japan (present), 17:Celgene Corporation, Overland Park, KS, USA, 18:Celgene K.K., Tokyo, Japan

The hematopoietic reconstitution of mice with HLA(-) HSPCs derived from aplastic anemia patients

[演者] Mahmoud I. Elbadry:1,2
[著者] Luis Espinoza:1, Takamasa Katagiri:3, Noriharu Nakagawa:1, Tatsuya Imi:1, Yoshinori Yoshida:4, Kazuhisa Chonabayashi:4, Katsuto Takenaka:5, Koichi Akashi:5, Shinji Nakao:1
1:Hematology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, 2:Internal Medicine, Hematology Division, Faculty of Medicine, Sohag University, Egypt, 3:Clinical Laboratory Sciences, Kanazawa University Graduate School of Health Sciences, Kanazawa, Japan, 4:Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan, 5:Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan

Molecular mechanisms of clonal hematopoiesis by SLIT1-mutant HSC clones in acquired aplastic anemia

[演者] Kohei Hosokawa (細川 晃平):1
[著者] Luis Espinoza:1, Dao Thi An:1, Chizuru Saito (斉藤 千鶴):1, Takamasa Katagiri (片桐 孝和):2, Ai Harashima (原島 愛):3, Akinori Kanai (金井 昭教):4, Akari Kazami (風見 亜花里):5, Hirotaka Matsui (松井 啓隆):4, Toshiya Inaba (稲葉 俊哉):4, Masafumi Taniwaki (谷脇 雅史):5, Yasuhiko Yamamoto (山本 靖彦):3, Shinji Nakao (中尾 眞二):1
1:Cellular Transplantation Biology, Kanazawa Univ., Kanazawa, Japan, 2:Medical, Pharmaceutical and Health Sciences, Kanazawa Univerisity, Kanazawa, Japan, 3:Biochemistry and Molecular Vascular Biology, Kanazawa University, Kanazawa, Japan, 4:Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan, 5:Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Establishment of in vivo and in vitro model of X-linked sideroblastic anemia by CRISPR/Cas9

[演者] Kei Saito (齋藤 慧):1
[著者] Tohru Fujiwara (藤原 亨):1, Masanobu Morita (守田 匡伸):2, Shunsuke Hatta (八田 俊介):1, Noriko Fukuhara (福原 規子):1, Yasushi Onishi (大西 康):1, Yukio Nakamura (中村 幸夫):3, Ritsuko Shimizu (清水 律子):4, Hideo Harigae (張替 秀郎):1
1:Dept. Hematol. and Rheumatol., Tohoku Univ., Sendai, Japan, 2:Dept. Medical Biochemistry, Tohoku Univ., Sendai, Japan, 3:Cell Engineering Div., RIKEN BioResource Center, Tsukuba, Japan, 4:Dept. Molecular Hematol., Tohoku Univ., Sendai, Japan

Functional analysis of congenital dyserythropoietic anemia (CDA) -specific iPS cells

[演者] Hiroshi Kohara (小原 洋志):1
[著者] Yoshie Ogawa (小川 由恵):1, Taiju Utsugisawa (槍澤 大樹):2, Chika Sakamoto (坂本 千香):3, Shohei Miyamoto (宮本 将平):1, Hitoshi Kanno (菅野 仁):2, Kenzaburo Tani (谷 憲三朗):1,3,4
1:Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2:Tokyo Women's Medical University, Tokyo, Japan, 3:Kyushu University, Fukuoka, Japan, 4:Kyushu University Hospital, Fukuoka, Japan

Non Hodgkin's lymphoma of the Waldeyer's ring: Clinical outcomes and patterns of failure

[演者] Tejshri Telkhade:1
[著者] Siddhartha Laskar:1, Jayant Goda:1, Nehal Khanna:1, Manju Sengar:2, Navin Khatry:2, Epari Shridhar:3, Sumeet Gujral:3, Tanuja Shet:3, Venkatesh Rangrajan:4, Hasmukh Jain:2, Bhausaheb Bagal:2
1:Radiation Oncology, Tata Memorial Hospital, Mumbai, India, 2:Medical Oncology, Tata Memorial Hospital, Mumbai, India, 3:Department of Pathology, Tata Memorial Hospital, Mumbai, India, 4:Department of Bio-Imaging, Tata Memorial Hospital, Mumbai, India

Bendamustine + rituximab in the treatment of indolent lymphoma, updated results of the StiL studies

[演者] Mathias Rummel:1
[著者] Frank Kauff:1, Juergen Barth:1
1:Hematology, University Hospital Giessen, Germany

Retrospective analysis of advanced stage MZL 132 cases treated with R-CVP: CISL trial

[演者] Sung Yong Oh:1
[著者] Won Seog Kim:2, Jin Seok Kim:3, Seok Jin Kim:2, Kwai Han Yoo:4, Jae Hoon Lee:4, Gyeong-Won Lee:5, Ji-Hyun Lee:1, Dok Hyun Yoon:6, Won-Sik Lee:7, Hyo Jung Kim:8, Jae-Yong Kwak:9, Ho-Young Yhim:9, Hye Jin Kang:10, Jae-Cheol Jo:11, Yong Park:12, Ho Sup Lee:13, Cheolwon Suh:6
1:Dong-A University Hospital, Korea, 2:Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 3:Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 4:Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea, 5:Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine , Jinju, Korea, 6:Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 7:Department of Hemato/Oncology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea, 8:Department of Internal Medicine, Hallym Medical Center, Hallym University College of Medicine, Anyang, Korea, 9:Division of Hematology, Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea, 10:Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea, 11:Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea, 12:Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea, 13:Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Clinical profile of diffuse large cell lymphoma involving stomach: A single-institution analysis

[演者] Satoshi Maruyama (丸山 聡):1
[著者] Hideki Tsujimura (辻村 秀樹):1, Hiroyuki Arai (新井 裕之):1, Akiyasu Sato (佐藤 昌靖):1, Keiko Ono (小野 敬子):1, Takeaki Sugawara (菅原 武明):1, Mikiko Ise (伊勢 美樹子):1, Kyoya Kumagai (熊谷 匡也):1
1:Division of Hematology-Oncology, Chiba Cancer Center, Japan

Clinical characterization of gastrointestinal lymphoma (GIL) in a single institute

[演者] Kosuke Arai (新井 康祐):1
[著者] Yotaro Motomura (本村 鷹多朗):1, Saeko Sonokawa (園川 佐絵子):1, Sayaka Suzuki (鈴木 さやか):1, Takashi Kumagai (熊谷 隆志):1
1:Department of Hematology, Ome Municipal General Hospital, Tokyo, Japan

AG-348, a pyruvate kinase activator, for pyruvate kinase deficiency: Results from the drive PK study

[演者] Hitoshi Kanno:1
[著者] Rachael F. Grace:2, D. Mark Layton:3, Frederic Galacteros:4, Christian Rose:5, Wilma Barcellini:6, D. Holmes Morton:7, Eduard Van Beers:8, Hassan Yaish:9, Yaddanapudi Ravindranath:10, Kevin H. M. Kuo:11, Sujit Sheth:12, Janet L. Kwiatkowski:13, Bruce Silver:14, Charles Kung:15, Marvin Cohen:16, Hua Yang:15, Penelope A. Kosinski:15, Lei Hua:15, Ann J. Barbier:15, Bertil Glader:17
1:Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University, Tokyo, Japan, 2:Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA, 3:Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK, 4:Unite des Maladies Genetiques du Globule Rouge, CHU Henri Mondor, Creteil, France, 5:Hopital Saint Vincent de Paul, Lille, France, 6:Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 7:Central Pennsylvania Clinic, Belleville, PA, USA, 8:Universitair Medisch Centrum Utrecht, Utrecht, Netherlands, 9:University of Utah, Salt Lake City, UT, USA, 10:Wayne State University School of Medicine-Children's Hospital of Michigan, Detroit, MI, USA, 11:University of Toronto, Toronto, ON, Canada, 12:Weill Cornell Medical College, New York, NY, USA, 13:Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA, 14:Bruce A Silver Clinical Science and Development, Dunkirk, MD, USA, 15:Agios Pharmaceuticals, Inc., Cambridge, MA, USA, 16:MBC Pharma Solutions, Newtown, PA, USA, 17:Stanford University School of Medicine, Palo Alto, CA, USA

Pregnancy outcomes in Paroxysmal Nocturnal Hemoglobinuria depending on the therapeutic approach

[演者] Maria Vinogradova:1
[著者] Alexander Kulagin:2, Tatiana Kirsanova:1, Roman Shmakov:1
1:Federal Scientific Centre for Obstetrics, Gynecology and Perinatology, Russia, 2:Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation

Characterization of new Hb variant: Hb Hachioji (β62 (E6) c.187C>T or A62V)

[演者] Mella Ferania:1
[著者] Yasuhiro Yamashiro:1, Yuki Amao:1, Shizuka Ogata:1, Fukumi Ohto:1, Kosuke Nunoda:2, Yukio Hattori:3
1:Departement of Health Sciences, Graduate School of Medicine, Yamaguchi University, Japan, 2:Kitanodai Medical Clinic, Hachioji, Japan, 3:Department of Clinical Laboratory, Yamaguchi Saiseikai General Hospital, Yamaguchi, Japan

Heterogeneous KCNN4 or PIEZO1 gene mutations cause dehydrated hereditary stomatocytosis in Japan

[演者] Taiju Utsugisawa (槍澤 大樹):1
[著者] Toshiyuki Yamamoto (山本 俊至):2, Takuya Iwasaki (岩崎 拓也):1, Takako Aoki (青木 貴子):1, Yoshio Okamoto (岡本 好雄):1, Michiko Muraoka (村岡 倫子):3, Kenichiro Watanabe (渡邉 健一郎):4, Yoshiya Katsura (桂 善也):5, Hiromi Ogura (小倉 浩美):1, Hitoshi Kanno (菅野 仁):1
1:Dept. Transf. Med. Cell Process, Tokyo Women's Med. Univ., Tokyo, Japan, 2:Inst. Med. Genet., Tokyo Women's Med. Univ., Tokyo, Japan, 3:Dept. Ped., Natl. Hosp. Org. Fukuyama Med. Ctr., Fukauyama, Japan, 4:Dept. Hematol. Oncol., Shizuoka Children's Hosp., Shizuoka, Japan, 5:Dept. Endocrinol. Metab., Tokyo Med. Univ., Ibaraki Med. Ctr., Ami, Japan

Prospective Analysis of BK viremia

[演者] Erden Atilla:1
[著者] Pinar Ataca Atilla:1, Can Ates:2, Istar Dolapci:3, Alper Tekeli:3, Pervin Topcuoglu:1
1:Department of Hematology, Ankara University School of Medicine, Turkey, 2:Department of Bioistatistics, Ankara University School of Medicine, 3:Department of Microbiology, Ankara University School of Medicine

Identifying potential barriers to sperm cryopreservation among Pakistani male cancer patients

[演者] Natasha Ali:1
[著者] Nida Latif:1
1:Aga Khan University, Pakistan

Outcomes after cord blood transplantation for myelodysplastic syndromes in children

[演者] Nao Yoshida (吉田 奈央):1
[著者] Kenichiro Watanabe (渡邉 健一郎):2, Asahito Hama (濱 麻人):3, Shohei Yamamoto (山本 将平):4, Hiromasa Yabe (矢部 普正):5, Jiro Inagaki (稲垣 二郎):6, Masami Inoue (井上 雅美):7, Yoshiyuki Takahashi (高橋 義行):3, Koji Kato (加藤 剛二):1, Yoshiko Hashii (橋井 佳子):8, Atsushi Sato (佐藤 篤):9, Yoshiko Atsuta (熱田 由子):10, Daiichiro Hasegawa (長谷川 大一郎):11
1:Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 2:Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan, 3:Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4:Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan, 5:Cell Transplantation and Regenerative Medicine, Tokai University, Isehara, Japan, 6:Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan, 7:Osaka Women's and Children's Hospital, Izumi, Japan, 8:Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan, 9:Hematology and Oncology, Miyagi Children's Hospital, Sendai, Japan, 10:Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan, 11:Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan

Prognosis of relapse after first hematopoietic cell transplantation for pediatric acute leukemia

[演者] Hirotoshi Sakaguchi (坂口 大俊):1
[著者] Manabu Wakamatsu (若松 学):1, Ayako Yamamori (山森 彩子):1, Ryo Maemura (前村 遼):1, Sayoko Doisaki (土居崎 小夜子):1, Nao Yoshida (吉田 奈央):1, Koji Kato (加藤 剛二):1
1:Pediatric Hematol. Oncol., Japanese Red Cross Nagoya First Hospital

Effect of glutathione S-transferase gene variations on busulfan pharmacokinetics in children

[演者] Atsushi Narita (成田 敦):1
[著者] Masayuki Miyazaki (宮崎 雅之):2, Motoharu Hamada (濱田 太立):1, Shinsuke Kataoka (片岡 伸介):1, Daisuke Ichikawa (市川 大輔):1, Rieko Taniguchi (谷口 理恵子):1, Norihiro Murakami (村上 典寛):1, Daiei Kojima (小島 大英):1, Kyogo Suzuki (鈴木 喬悟):1, Eri Nishikawa (西川 英里):1, Nozomu Kawashima (川島 希):1, Yusuke Okuno (奥野 友介):1, Hideki Muramatsu (村松 秀城):1, Nobuhiro Nishio (西尾 信博):1, Asahito Hama (濱 麻人):1, Hirotoshi Sakaguchi (坂口 大俊):3, Nao Yoshida (吉田 奈央):3, Koji Kato (加藤 剛二):3, Taku Nagai (永井 拓):2, Kiyofumi Yamada (山田 清文):2, Seiji Kojima (小島 勢二):1, Yoshiyuki Takahashi (高橋 義行):1
1:Dept. Pediatrics, Nagoya University, Nagoya, 2:Dept. Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Nagoya, 3:Pediatric Hematology/Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya

Bosutinib vs Imatinib for newly diagnosed chronic myeloid leukemia (CML): Results of the BFORE trial

[演者] Jorge E. Cortes:1
[著者] Carlo Gambacorti-Passerini:2, Michael Deininger:3, Michael J. Mauro:4, Thuan Heng Charles Chuah:5, Dong-Wook Kim:6, Laurence Reilly:7, Allison Jeynes-Ellis:7, Eric Leip:8, Nathalie Bardy-Bouxin:9, Andreas Hochhaus:10, Tim H. Brummendorf:11, on behalf of the BFORE Study Investigators
1:University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2:University of Milano-Bicocca, Monza, IT, 3:University of Utah, Salt Lake City, UT, USA, 4:Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5:Singapore General Hospital, Duke-NUS Graduate Medical School, Singapore, SG, 6:Seoul St. Marys Hospital, Seoul, KR, 7:Avillion LLP, London, UK, 8:Pfizer Inc., Cambridge, MA, USA, 9:Pfizer Global Research and Development, Paris, FR, 10:Klinik für Innere Medizin II, Universitatsklinikum Jena, Jena, DE, 11:Universitatsklinikum RWTH Aachen, Aachen, DE

DMR and TFR following 2-year consolidation by Nilotinib in patients with CML: STAT trial in Japan

[演者] Naoto Takahashi (高橋 直人):1
[著者] Chiaki Nakaseko (中世古 知昭):2, Kaichi Nishiwaki (西脇 嘉一):3, Hisashi Wakita (脇田 久):4, Michihide Tokuhira (得平 道英):5, Jun Kuroki (黒木 淳):6, Hideo Kimura (木村 英夫):7, Kohshi Ohishi (大石 晃嗣):8, Hideyoshi Noji (野地 秀義):9, Kinuko Mitani (三谷 絹子):10, Hitoshi Ogasawara (小笠原 仁):11, Masaaki Noguchi (野口 雅章):12, Hiroshi Handa (半田 寛):13, Kazuhisa Fujikawa (藤川 一寿):14, Osamu Iwase (岩瀬 理):15, Fumihiko Kimura (木村 文彦):16, Masatomo Miura (三浦 昌朋):17
1:Hematol., Akita Univ., Akita, Japan, 2:Hemato., Chiba Univ., Chiba, Japan, 3:Oncology and Hematol., Jikei Univ. Kashiwa Hosp., Kashiwa, 4:Hematol. and Oncology, Japanese Red Cross Narita Hosp., Narita, 5:Hematol., Saitama Medical Univ., Kawagoe, 6:Intl. Med., Yuri General Hospital, Yurihonjo, 7:Hematology, Northern Fukushima Medical Center, Date, 8:Transfusion Service, Mie University Hospital, Tsu, 9:Med. Oncol./ Hematol., Fukushima Medical University, Fukushima, 10:Hematol. and Oncol., Dokkyo Medical University, Mibu-machi, 11:Hematol. and Oncol., Odate Municipal Hospital, Odate, 12:Hematol., Juntendo Univ. Urayasu Hosp., Urayasu, 13:Hematol., Gunma Univ. Hosp., Maebashi, 14:Hematol., Chibaken Saiseikai Narashino Hosp., Narashino, 15:Hematol., Tokyo Medical Univ. Hachioji Medical Center, Hachioji, 16:Hematol., National Defense Medical College Hosp., Tokorozawa, 17:Pharmacy, Akita Univ. Hosp., Akita

Phase 1/2 study of Ponatinib in Japanese patients (Pts) with Ph+ leukemia: 3-year follow-up results

[演者] Kohei Kyo:1
[著者] Arinobu Tojo:2, Taiichi Kyo:3, Kazuhito Yamamoto:4, Hirohisa Nakamae:5, Naoto Takahashi:6, Yukio Kobayashi:7, Tetsuzo Tauchi:8, Shinichiro Okamoto:9, Koichi Miyamura:10, Kiyohiko Hatake:11, Hiromi Iwasaki:12, Itaru Matsumura:13, Noriko Usui:14, Tomoki Naoe:15, Heinrich Farin:16, Kazuma Ohyashiki:17
1:Hiroshima Red Cross and Atomic Bomb Survivors Hospital, Hiroshima, Japan, 2:The University of Tokyo, The Institute of Medical Science, Tokyo, Japan, 3:Itsukaichi Memorial Hospital, Hiroshima, Japan, 4:Aichi Cancer Center Hospital, Aichi, Japan, 5:Osaka City University Hospital, Osaka, Japan, 6:Akita University Hospital, Akita, Japan, 7:National Cancer Center Hospital, Tokyo, Japan, 8:Tokyo Medical University Hospital, Tokyo, Japan, 9:Keio University Hospital, Tokyo, Japan, 10:Japanese Red Cross Nagoya First Hospital, Aichi, Japan, 11:The Cancer Institute Hospital Japanese Foundation for Cancer Research, Tokyo, Japan, 12:Kyushu University Hospital, Fukuoka, Japan, 13:Kinki University Hospital, Osaka, Japan, 14:The Jikei University Daisan Hospital, Tokyo, Japan, 15:National Hospital Organization Nagoya Medical Center, Aichi, Japan, 16:ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, 17:Tokyo Medical University Hospital, Tokyo, Japan

Successful dasatinib cessation after 2-year consolidation, the result of D-STOP trial

[演者] Takashi Kumagai (熊谷 隆志):1
[著者] Chiaki Nakaseko (中世古 知昭):2, Kaichi Nishiwaki (西脇 嘉一):3, Chikashi Yoshida (吉田 近思):4, Kazuteru Ohashi (大橋 一輝):5, Naoki Takezako (竹迫 直樹):6, Hina Takano (高野 弥奈):7, Yasuji Kozai (香西 康司):8, Tadashi Murase (村瀬 忠):9, Kosei Matsue (末永 孝生):10, Satoshi Morita (森田 智視):11, Junichi Sakamoto (坂本 純一):12, Hisashi Wakita (脇田 久):13, Hisashi Sakamaki (坂巻 壽):5, Koiti Inokuchi (猪口 孝一):14
1:Department of Hematology, Ome Municipal General Hospital, Tokyo Japan, 2:Department of Hematology, Chiba University Hospital, Chiba, Japan, 3:Clinical Oncology and Hematology, Jikei University, Kashiwa Hospital, Chiba, Japan, 4:Department of Hematology, Mito Medical Center, Higashiibarakigun, Japan, 5:Hematology Division, Komagome Hospital, Tokyo, Japan, 6:Dept. Hematol., National Hospital Organization Disaster Medical Center, Tachikawa, Japan, 7:Department of Hematology, Musashino Red Cross Hospital, Musashino, Japan, 8:Dept. Hematology, Tokyo Metropolitan Tama Synthesis Medical Center, Tokyo, Japan, 9:Dept. Laboratory Medicine, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan, 10:Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan, 11:Department of Biomedical Statistics and Bioinformatics, Kyoto University, Kyoto, Japan, 12:Tokai Central Hospital, Kakamigahara, Japan, 13:Div. Hematology and Oncology, Narita Red Cross Hosp., Narita, Japan, 14:Department of Hematology, Nippon Medical School, Tokyo, Japan

Interim analysis of the New TARGET study, the observational study for newly diagnosed CML in Japan

[演者] Yuichi Ishikawa (石川 裕一):1
[著者] Hitoshi Kiyoi (清井 仁):1, Ritsuro Suzuki (鈴木 律朗):2, Tatsuya Kawaguchi (川口 辰哉):2, Naoto Takahashi (高橋 直人):2, Kazuhito Yamamoto (山本 一仁):2, Kazunori Ohnishi (大西 一功):2, Masahiro Kizaki (木崎 昌弘):2, Tomoki Naoe (直江 知樹):2, Itaru Matsumura (松村 到):2
1:Dept. Hematol./Oncol., Nagoya University Graduate School of Medicine, Nagoya, Japan, 2:The Japanese Society of Hematology, New Target Study Committee

Acute promyelocytic leukemia: a model of personalized medicine

[演者] Christine Chomienne:1
1:Institut Universitaire d'Hematologie, Hopital Saint Louis, France

MDS stem cell behavior: Can it predict clinical outcomes?

[演者] Stephen D. Nimer:1
1:Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, USA

Current and future management of FL referring to biomarkers/response criteria surrogate marker

[Speaker] Michele Ghielmini:1
1:Oncology Institute of Southern Switzerland in Bellinzona, Switzerland

Multiple Myeloma: Changing the present, Creating the future

[Speaker] Suzanne Lentzsch:1
1:Columbia University Medical Center, USA

Combinations of novel agents in the treatment of Multiple Myeloma

[Speaker] Pieter Sonneveld:1
1:Erasmus MC Cancer Institute

The 3rd generation TKI for Ph+leukemia treatment

[Speaker] Elias Jabbour:1
1:Leukemia Department, MD Anderson Cancer Center

Considerations for TKI treatment in CML

[Speaker] Jorge Eduardo Cortes:1
1:Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Precision molecules changing the treatment landscape of AML

[Speaker] Andrew Wei:1
1:MONASH University, Austraria

T-cell lymphomas: contemporary treatment strategies

[Speaker] Andrei Shustov:1
1:Division of Hematology University of Washington

Latest Advances in Autologous Stem Cell Mobilization

[Speaker] Mohamad Mohty:1
1:Department of Hematology, Hematology and cellular therapy Department, Hospital Saint-Antoine, and University Pierre & Marie Curie, Paris, France

Introduction to the 2016 revised WHO criteria for MPN

[演者] Kazuya Shimoda (下田 和哉):1
1:Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan

Mechanism of mutant molecular chaperone-induced development of myeloproliferative neoplasms

[演者] Marito Araki (荒木 真理人):1
1:Dept. Transfus. Med. & Stem Cell Reg., Juntendo Univ., Tokyo, Japan

Translating recent cancer genome discoveries to patient tailored clinical intervention protocols

[演者] Elli Papaemmanuil:1
1:Memorial Sloan Kettering Cancer Center, USA

Clinical implications of clonal hematopoiesis

[演者] Rafael Bejar:1
1:Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, USA

Somatic mutation in MDS and its effect on outcome

[演者] Tetsuichi Yoshizato (吉里 哲一):1
1:Department of Pathology and Tumor Biology, Kyoto Univ., Kyoto, Japan

Impact of mismatched HLA on graft-versus-host disease in unrelated stem cell transplantation

[演者] Satoko Morishima (森島 聡子):1
1:Endocrinology, Diabetes, Metabolism, Hematology, Rheumatology, Ryukyus Univ., Okinawa, Japan

Immunogenetics of unrelated donor hematopoietic cell transplantation

[演者] Effie Wang Petersdorf:1
1:Fred Hutchinson Cancer Research Center, Seattle, WA, USA

New insight into Treg homeostasis and GVHD in the era of peri-transplant immune modulation

[演者] Ken-ichi Matsuoka (松岡 賢市):1
1:Department of Hematology and Oncology, Okayama University, Okayama, Japan

Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources

[演者] Yoshihiro Inamoto (稲本 賢弘):1
1:Division of HSCT, National Cancer Center Hospital, Tokyo, Japan

ATG for prevention of chronic GvHD after allogeneic stem cell transplantation

[演者] Nicolaus Kröger:1
1:Stem Cell Transplantation, University Medical Center, Hamburg, Germany

ARID5B activates the TAL1-induced core regulatory circuit and the MYC oncogene in T-ALL

[演者] Wei Zhong Leong:1
[著者] Shi Hao Tan:1, Phuong Cao Thi Ngoc:1, Stella Amanda:1, Alice Wei Yee Yam:1, Wei-Siang Liau:1, Zhiyuan Gong:2, Lee N. Lawton:1, Daniel G. Tenen:1,3,4,5, Takaomi Sanda:1,5
1:Cancer Science Institute of Singapore, National University of Singapore, Singapore, 2:Department of Biological Sciences, National University of Singapore, Singapore, 3:Harvard Medical School, Boston, Massachusetts, USA, 4:Harvard Stem Cell Institute, Boston, Massachusetts, USA, 5:Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Genetic and epigenetic landscape of pediatric T-cell acute lymphoblastic leukemia (T-ALL)

[演者] Shunsuke Kimura (木村 俊介):1,2
[著者] Masafumi Seki (関 正史):1, Tomoko Kawai (河合 智子):3, Kenichi Yoshida (吉田 健一):4, Yuichi Shiraishi (白石 友一):5, Kenichi Chiba (千葉 健一):5, Tomoya Isobe (磯部 知弥):1, Hiroo Ueno (上野 浩生):4, Hiromichi Suzuki (鈴木 啓道):4, Keisuke Kataoka (片岡 圭亮):4, Hiroko Tanaka (田中 洋子):5, Masaharu Akiyama (秋山 政晴):6, Kentaro Ohki (大木 健太郎):7, Toshihiko Imamura (今村 俊彦):8, Nobutaka Kiyokawa (清河 信敬):7, Masao Kobayashi (小林 正夫):2, Katsuyoshi Koh (康 勝好):9, Ryoji Hanada (花田 良二):9, Atsushi Manabe (真部 淳):10, Akira Ohara (小原 明):11, Masashi Sanada (真田 昌):12, Yasuhide Hayashi (林 泰秀):13, Kenichiro Hata (秦 健一郎):3, Satoru Miyano (宮野 悟):5, Seishi Ogawa (小川 誠司):4, Junko Takita (滝田 順子):1
1:Department of Pediatrics, The University of Tokyo Hosipital, Tokyo, Japan, 2:Department of Pediatrics, Hiroshima University, Hiroshima, Japan, 3:Maternal/Fetal-Biology, National Center for Child Health/Development, Tokyo, Japan, 4:Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5:Human-Genome Center, Institute of Medical Science, Tokyo University, Tokyo, Japan, 6:Department of Pediatrics, The Jikei University, Tokyo, Japan, 7:Hematology/Oncology, National Center for Child Health and Development, Tokyo, Japan, 8:Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan, 9:Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, 10:Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan, 11:Department of Pediatrics, Toho University, Tokyo, Japan, 12:National Hospital Organization Nagoya Medical Center, Nagoya, Japan, 13:Gunma Children's Medical Center, Shibukawa, Gunma, Japan

Hypoxic adaptation of leukemic cells in the CNS affords a therapeutic strategy targeting VEGFA

[演者] Itaru Kato (加藤 格):1,2,3
[著者] Yoko Nishinaka-Arai (西中 瑶子):2, Masahiro Nakamura (中村 正裕):4, Ayse Akarca:5, Akira Niwa (丹羽 明):2, Hiroki Ozawa (小澤 弘樹):3, Kenichi Yoshida (吉田 健一):6, Makiko Mori (森 麻希子):7, Dapeng Wang:2,8, Makiko Morita (森田 真紀子):9, Hiroo Ueno (上野 浩生):1,6, Yusuke Shiozawa (塩澤 裕介):10, Yuichi Shiraishi (白石 友一):11, Satoru Miyano (宮野 悟):11, Rajeev Gupta:3, Katsutsugu Umeda (梅田 雄嗣):1, Kenichiro Watanabe (渡邉 健一郎):12, Katsuyoshi Koh (康 勝好):7, Souichi Adachi (足立 壮一):9, Toshio Heike (平家 俊男):1, Megumu Saito (斎藤 潤):2, Masashi Sanada (真田 昌):13, Seishi Ogawa (小川 誠司):6, Teresa Marafioti:5, Akira Watanabe (渡辺 亮):4, Tatsutoshi Nakahata (中畑 龍俊):2, Tariq Enver:3
1:Pediatrics, Kyoto Univ., Kyoto, Japan, 2:Department of Clinical Application, CiRA, Kyoto University, Kyoto, Japan, 3:Cancer Institute, University College London, London, United Kingdom, 4:Sequencing Core Facility, CiRA, Kyoto University, Kyoto, Japan, 5:Department of Cellular Pathology, University College London, London, United Kingdom, 6:Graduate School of Medicine, Kyoto University, Kyoto, Japan, 7:Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, 8:Department of Plant Sciences, University of Oxford, Oxford, United Kingdom, 9:Human Health Sciences, Kyoto University, Kyoto, Japan, 10:Department of Pediatrics, The University of Tokyo, Tokyo, Japan, 11:Institute of Medical Science, The University of Tokyo, Tokyo, Japan, 12:Department of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan, 13:Clinical Research Center, Nagoya Medical Center, Aichi, Japan

Loss of Rheb suppresses T-ALL development without severe defects in normal hematopoiesis

[演者] Masaya Ueno (上野 将也):1
[著者] Hui Peng (彭 卉):1, Atsuo Kasada (笠田 篤郎):1, Takayuki Hoshii (星居 孝之):1, Atsushi Hirao (平尾 敦):1
1:Cancer Research Institute, Kanazawa University

Recurrent MEF2D fusions in pediatric B-precursor acute lymphoblastic leukemia and lymphoma

[演者] Kentaro Ohki (大木 健太郎):1,2
[著者] Yuya Saito (斎藤 雄弥):2, Shinsuke Hirabayashi (平林 真介):2, Motohiro Kato (加藤 元博):1,2, Kazuhiko Nakabayashi (中林 一彦):1, Myoung-Ja Park (朴 明子):2,3, Manabu Sotomatsu (外松 学):2,3, Kenichiro Hata (秦 健一郎):1, Hiroyuki Takahashi (高橋 浩之):2, Takashi Fukushima (福島 敬):2, Katsuyoshi Koh (康 勝好):2, Atsushi Manabe (真部 淳):2, Akira Ohara (小原 明):2, Yasuhide Hayashi (林 泰秀):4, Nobutaka Kiyokawa (清河 信敬):1,2
1:Natl. Cent. for Child Health and Dev., Tokyo, Japan, 2:Tokyo Childrens Cancer Study Group, Japan, 3:Dept. of Hematol. & Oncol., Gunma Childrens Medical Center, Gunma, Japan, 4:Japanese Red Cross Gunma Blood Center, Maebashi, Japan

Effect of prior lines of therapy and treatment exposure on Daratumumab with Rd in RRMM: POLLUX

[演者] Torben Plesner:1
[著者] Meletios A. Dimopoulos:2, Paul Richardson:3, James Morton:4, Naoki Takezako:5, Kihyun Kim:6, Christopher Chiu:7, Kaida Wu:7, Xiang Qin:7, Jordan Schecter:8, Jesus San-Miguel:9
1:Vejle Hospital and University of Southern Denmark, Denmark, 2:National and Kapodistrian University of Athens, Athens, Greece, 3:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 4:Icon Cancer Care, South Brisbane, QLD, Australia, 5:Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan, 6:Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 7:Janssen Research & Development, LLC, Spring House, PA, USA, 8:Janssen Research & Development, LLC, Raritan, NJ, USA, 9:Clinica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain

Daratumumab combined with Rd versus Rd alone for RRMM (POLLUX): Efficacy and safety update

[演者] Kenshi Suzuki:1
[著者] Hareth Nahi:2, P. Joy Ho:3, Shinsuke Iida:4, Miles Prince:5, Jin Seok Kim:6, Christopher Chiu:7, Kaida Wu:7, Xiang Qin:7, Jordan Schecter:8, Philippe Moreau:9
1:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, 2:Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden, 3:Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, 4:Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5:University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia, 6:Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea, 7:Janssen Research & Development, LLC, Spring House, PA, USA, 8:Janssen Research & Development, LLC, Raritan, NJ, USA, 9:Hematology, University Hospital Hotel-Dieu, Nantes, France

Japanese subanalysis of ELOQUENT-2: 4-y follow-up of Elotuzumab + Len/Dex for multiple myeloma (MM)

[演者] Hiroshi Handa (半田 寛):1
[著者] Kazutaka Sunami (角南 一貴):2, Kenshi Suzuki (鈴木 憲史):3, Kazuteru Ohashi (大橋 一輝):4, Shinsuke Iida (飯田 真介):5, Shinichiro Okamoto (岡本 真一郎):6, Kosei Matsue (末永 孝生):7, Masafumi Miyoshi (三好 昌史):8, Eric Bleickardt:9, Morio Matsumoto (松本 守生):10, Masafumi Taniwaki (谷脇 雅史):11
1:Division of Hematology, Gunma University Hospital, Maebashi, Japan, 2:Okayama Medical Center, Okayama, Japan, 3:Japanese Red Cross Medical Center, Tokyo, Japan, 4:Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 5:Nagoya City University Hospital, Nagoya, Japan, 6:Keio University Hospital, Tokyo, Japan, 7:Kameda Medical Center, Kamogawa, Japan, 8:Bristol-Myers Squibb K.K., Tokyo, Japan, 9:Bristol-Myers Squibb, New Jersey, USA, 10:Shibukawa Medical Center, Shibukawa, Japan, 11:University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

Impact of chromosomal abnormalities on the efficacy of lenalidomide treatment on multiple myeloma

[演者] Takashi Yoshida (吉田 嵩):1
[著者] Masaki Ri (李 政樹):1, Shiori Kinoshita (木下 史緒理):1, Haruhito Totani (戸谷 治仁):1, Yoshiaki Marumo (丸茂 義晃):1, Hirokazu Sasaki (佐々木 宏和):1, Takahiro Nakashima (中島 貴裕):1, Chie Kato (加藤 千絵):1, Takashi Kanamori (金森 貴之):1, Satsuki Murakami (村上 五月):1, Tomoko Narita (成田 朋子):1, Ayako Masaki (正木 彩子):1, Asahi Ito (伊藤 旭):1, Shigeru Kusumoto (楠本 茂):1, Takashi Ishida (石田 高司):1, Hirokazu Komatsu (小松 弘和):1, Shinsuke Iida (飯田 真介):1
1:Division of Hematology & Oncology, Nagoya City University Hospital, Nagoya, Japan

DRd vs Rd in Japanese patients with RRMM: Subgroup analysis of the phase 3 POLLUX study

[演者] Shinsuke Iida:1
[著者] Meletios A. Dimopoulos:2, Naoki Takezako:3, Kaida Wu:4, Xiang Qin:4, Ming Qi:4, Kenshi Suzuki:5
1:Nagoya City University Graduate School of Medical Sciences, Japan, 2:National and Kapodistrian University of Athens, Athens, Greece, 3:Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan, 4:Janssen Research & Development, LLC, Spring House, PA, USA, 5:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

Distinct leukemia-initiating properties of APL by genomic structure; Short vs. long isoform PML-RARa

[演者] Mariko Minami (南 満理子):1
[著者] Yoshikane Kikushige (菊繁 吉謙):1, Toshihiro Miyamoto (宮本 敏浩):1, Koichi Akashi (赤司 浩一):1
1:Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan

Paradoxical enhancement of leukemogenesis in AML with moderately-attenuated RUNX1 expressions

[演者] Shintaro Maeda (前田 信太郎):1
[著者] Ken Morita (森田 剣):1, Kensho Suzuki (鈴木 健聖):1, Junichi Taniguchi (谷口 純一):2, Hiroshi Sugiyama (杉山 弘):2, Souichi Adachi (足立 壮一):1,3, Yasuhiko Kamikubo (上久保 靖彦):1
1:Department of Human Health Sciences, Kyoto University, Kyoto, Japan, 2:Department of Chemistry, Graduate School of Science, Kyoto University, 3:Department of Pediatrics, Graduate School of Medicine, Kyoto University

A DNA repair gene, OGG1 affects the relapse risk of acute myeloid leukemia

[演者] Nanami Gotoh (後藤 七海):1
[著者] Takayuki Saitoh (齋藤 貴之):1, Noriyuki Takahashi (高橋 範行):1, Rumi Ino (井野 瑠美):1, Yuya Kitamura (北村 裕也):1, Maaya Awata (粟田 真彩):1, Rei Ishihara (石原 領):1, Masumi Ohata (大圃 真純):1, Yukihiro Kanai (金井 敬海):1, Keisuke Murata (村田 圭祐):1, Yuki Murakami (村上 有希):1, Saki Watanabe (渡辺 早貴):1, Kazuki Honma (本間 和貴):1, Yusuke Minato (湊 雄介):2, Tetsuhiro Kasamatsu (笠松 哲光):1, Takumi Hoshino (星野 匠臣):3, Toru Sakura (佐倉 徹):3, Hiroaki Shimizu (清水 啓明):4, Takuma Ishizaki (石埼 卓馬):4, Akihiko Yokohama (横濱 章彦):5, Makiko Takizawa (滝沢 牧子):4, Hiromi Koiso (小磯 博美):4, Norifumi Tsukamoto (塚本 憲史):4, Hiroshi Handa (半田 寛):4, Hirokazu Murakami (村上 博和):1
1:Graduate School of Health Sciences, Gunma University, Gunma, Japan, 2:Department of Virology and Preventive Medicine, Gunma University, Gunma, Japan, 3:Saiseikai Maebashi Hospital, Gunma, Japan, 4:Department of Medicine and Clinical Sciences, Gunma University, Gunma, Japan, 5:Division of Blood Transfusion Service, Gunma University Hospital, Gunma, Japan

Circadian clock gene, SHARP1 is an oncogenic driver in MLL-AF6 acute myeloid leukemia

[演者] Akihiko Numata (沼田 晃彦):1,2
[著者] Koichi Akashi (赤司 浩一):1, Daniel G. Tenen:2
1:Hematology/Oncology/Cardiovascular Medicine, Kyushu University Hospital, 2:Cancer Science Institute of Singapore, National University of Singapore, Singapore

Eya2 is critical for an aberrant self-renewal in PLZF-RARA-induced leukemogenesis

[演者] Ryoichi Ono (小埜 良一):1
[著者] Masahiro Masuya (桝屋 正浩):2, Satomi Ishii (石井 聡美):1, Naoyuki Katayama (片山 直之):2, Tetsuya Nosaka (野阪 哲哉):1
1:Dept. Microbiol. Mol. Genetics, Mie Univ. Grad. Sch. Med., Tsu, Japan, 2:Dept. Hematol. Oncol., Mie Univ. Grad. Sch. Med., Tsu, Japan

Phase 1 study of Venetoclax (VEN) in Japanese (JPN) patients (Pts) with hematologic malignancies

[演者] Noriko Fukuhara:1
[著者] Kiyohiko Hatake:2, Kazuhito Yamamoto:3, Shigeru Kusumoto:4, Koji Izutsu:5, Ilseung Choi:6, Hirokazu Nagai:7, Yukio Kobayashi:8, Masayuki Shintani:9, Junjiro Saeki:9, Andrew Roberts:10, Paulo Maciag:10, Suresh K. Agarwal:10, Ahmed Hamed Salem:10, Kevin J. Freise:10, Tsukasa Kiriyama:9, Kensei Tobinai:8
1:Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 2:Department of Hematology and Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 3:Department of Clinical Research and Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, 4:Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5:Department of Hematology, Toranomon Hospital, Minato-ku, Tokyo, Japan, 6:Department of Hematology, National Kyushu Cancer Center Hospital, Fukuoka, Japan, 7:Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan, 8:Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, 9:AbbVie GK, Tokyo, Japan, 10:AbbVie Inc., North Chicago, IL, USA

Identification of IRAK-M as a key molecule in the pathogenesis of chronic lymphocytic leukemia

[演者] Yoshikane Kikushige (菊繁 吉謙):1
[著者] Toshihiro Miyamoto (宮本 敏浩):2, Koichi Akashi (赤司 浩一):2
1:Dept. of Medicine and Biosystemic Sciences, Kyushu University, Fukuoka, Japan, 2:Kyushu University, Fukuoka, Japan

Ibrutinib (Ibr) in untreated patients ≥65 with chronic lymphocytic leukemia (CLL): Updated data

[演者] Peter Hillmen:1
[著者] Paul Barr:2, Tadeusz Robak:3, Carolyn Owen:4, Alessandra Tedeschi:5, Osnat Bairey:6, Nancy Bartlett:7, Steven Coutre:8, Lori Styles:9, Paolo Ghia:10
1:The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK, 2:University of Rochester Medical Center, Rochester, NY, USA, 3:Medical University of Lodz, Poland, 4:Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, 5:ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 6:Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel, 7:Washington University School of Medicine, St. Louis, MO, USA, 8:Stanford University School of Medicine, Stanford, CA, USA, 9:Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA, 10:L’Università Vita-Salute San Raffaele Ospedale-Milano, Milan, Italy

First line Bendamustine plus Rituximab in chronic lymphocytic leukemia. The MDA-CLL-2015-02 study

[演者] Adolfo de la Fuente:1
[著者] Maria Jose Terol:2, Begona Navas:3, Antonio Gutierrez:4, Marta Callejas:5, Jose Antonio Garcia Marco:6, Maria Dolores Garcia-Malo:7, Javier de la Serna:8, Isabel Gonzalez Gascon y Marin:9, Laura Garcia Sanchis:10, Monica Ballesteros:11, Celina Benavente:12, Isidro Jarque:13, Juliana Ochoa Gullon:12, Paola Beneit:14, Raquel de Ona:1, Carlos Montalban:1, Monica Estevez:1, Rebeca Iglesias:1, Antonio Diaz-Lopez:15, Patricia Baltasar:16
1:MD Anderson CC, Spain, 2:H. Clinico de Valencia, 3:H. U. Moncloa Madrid, 4:H. Son espases Palma de Mallorca, 5:H. U. Principe de Asturias Alcala de Henares Madrid, 6:H. U. Puerta de Hierro Madrid, 7:H. U. Morales Meseguer Murcia, 8:H. U. 12 de Octubre Madrid, 9:H. Infanta Leonor Madrid, 10:H. General de Castellon, 11:H. G. U. Gregorio Maranon, 12:H. Clinico san Carlos, 13:H. U. Politecnico La Fe de Valencia, 14:H. San Juan de Alicante, 15:Fundacion MD Anderson Madrid, 16:H. U. La Paz

Chronic lymphocytic leukemia/small lymphocytic lymphoma with 11q deletion

[演者] Tomoko Yamashita (山下 知子):1
[著者] Hiroki Tsutsumi (堤 大樹):1, Kota Yoshifuji (吉藤 康太):1, Tatsuya Saito (齊藤 達也):1, Yoshihiro Umezawa (梅澤 佳央):1, Ayako Nogami (野上 彩子):1, Ken Watanabe (渡邉 健):1, Toshikage Nagao (長尾 俊景):1, Masahide Yamamoto (山本 正英):1, Chizuko Sakashita (坂下 千瑞子):1, Ayako Arai (新井 文子):1, Norihiko Kawamata (川又 紀彦):1, Osamu Miura (三浦 修):1, Tetsuya Fukuda (福田 哲也):1
1:Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan

Daratumumab (D) combined with Vd versus Vd alone for RRMM (CASTOR): Efficacy and safety update

[演者] Suzanne Lentzsch:1
[著者] Ajay Nooka:2, Hang Quach:3, Noemi Horvath:4, Jae-Cheol Jo:5, Ho-Jin Shin:6, Christopher Chiu:7, Piruntha Thiyagarajah:8, Xiang Qin:7, Jordan Schecter:9, Andrew Spencer:10
1:Columbia University Medical Center, New York, NY, USA, 2:Winship Cancer Institute, Emory University, Atlanta, GA, USA, 3:St. Vincent's Hospital, University of Melbourne, Melbourne, Australia, 4:Department of Haematology, Royal Adelaide Hospital, SA Pathology, SA, Australia, 5:Ulsan University Hospital, Ulsan, South Korea, 6:Pusan National University Hospital, Busan, South Korea, 7:Janssen Research & Development, LLC, Spring House, PA, USA, 8:Janssen Research & Development, High Wycombe, UK, 9:Janssen Research & Development, LLC, Raritan, NJ, USA, 10:Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia

Effect of prior lines of therapy and treatment exposure on Daratumumab with Vd in RRMM: CASTOR

[演者] Suzanne Lentzsch:1
[著者] Katja Weisel:2, Cindy Lee:3, Je-Jung Lee:4, Christopher Chiu:5, Piruntha Thiyagarajah:6, Xiang Qin:5, Jordan Schecter:7, Maria-Victoria Mateos:8
1:Columbia University Medical Center, USA, 2:Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen, Germany, 3:Royal Adelaide Hospital, North Terrace, Adelaide, Australia, 4:Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun Jeollanamdo, South Korea, 5:Janssen Research & Development, LLC, Spring House, PA, USA, 6:Janssen Research & Development, High Wycombe, UK, 7:Janssen Research & Development, LLC, Raritan, NJ, USA, 8:University Hospital of Salamanca/IBSAL, Salamanca, Spain

Daratumumab with Bortezomib+Dexamethasone in Japanese pts with Relapsed/Refractory multiple myeloma

[演者] Tatsuo Ichinohe:1
[著者] Kenshi Suzuki:2, Shinsuke Iida:3, Naoki Takazako:4, Atsushi Shinagawa:5, Masayuki Aoki:6
1:Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, 2:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, 3:Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 4:Department of Hematology, National Disaster Medical Center of Japan, Tokyo, Japan, 5:Hitachi General Hospital, Hitachi, Japan, 6:Janssen Pharmaceutical K.K., Tokyo, Japan

Randomized phase II study of Bor/Dex vs Thal/Dex for relapsed/refractory multiple myeloma (JCOG0904)

[演者] Shinsuke Iida (飯田 真介):1,2
[著者] Masashi Wakabayashi (若林 将史):3, Kunihiro Tsukasaki (塚崎 邦弘):2,4, Kenichi Miyamoto (宮本 憲一):3, Dai Maruyama (丸山 大):2,5, Kazuhito Yamamoto (山本 一仁):2,6, Yoshifusa Takatsuka (高塚 祥芝):2,7, Shigeru Kusumoto (楠本 茂):1,2, Junya Kuroda (黒田 純也):2,8, Kiyoshi Ando (安藤 潔):2,9, Yoshitaka Kikukawa (菊川 佳敬):2,10, Yasufumi Masaki (正木 康史):2,11, Miki Kobayashi (小林 美希):2,12, Ichiro Hanamura (花村 一朗):2,13, Hiroaki Asai (朝井 洋晶):2,14, Hirokazu Nagai (永井 宏和):2,15, Kazuyuki Shimada (島田 和之):2,16, Norifumi Tsukamoto (塚本 憲史):2,17, Yoshiko Inoue (井上 佳子):2,18, Kensei Tobinai (飛内 賢正):2,5
1:Nagoya City Univ. Hosp., Nagoya, Japan, 2:JCOG-LSG, Japan, 3:JCOG Data Ctr., National Cancer Ctr., Tokyo, Japan, 4:National Cancer Ctr. Hosp. East, Kashiwa, Japan, 5:National Cancer Ctr. Hosp., Tokyo, Japan, 6:Aichi Cancer Ctr., Nagoya, Japan, 7:Imamura Bun-in Hosp., Kagoshima, Japan, 8:Kyoto Pref. Univ. Med., Kyoto, Japan, 9:Tokai Univ. Sch. Med., Isehara, Japan, 10:Kumamoto Univ. Hosp., Kumamoto, Japan, 11:Kanazawa Med. Univ., Kahoku-gun, Japan, 12:Japanese Red Cross Nagoya Daini Hosp., Nagoya, Japan, 13:Aichi Med. Univ., Nagakute, Japan, 14:Ehime Univ. Hosp., Toon, Japan, 15:NHO Nagoya Med. Ctr., Nagoya, Japan, 16:Nagoya Univ. Grad. Sch. Med., Nagoya, Japan, 17:Gunma Univ. Hosp., Maebashi, Japan, 18:NHO Kumamoto Med. Ctr., Kumamoto, Japan

Clinical manifestation and prognostic features of extramedullary plasmacytomas

[演者] Hyun Ae Jung:1,2
[著者] Chul Won Jung:2, Jun Ho Jang:2, Kihyun Kim:2
1:Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Dontan, South Korea, 2:Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

RUNX2 super enhancer promotes the development of blastic plasmacytoid dendritic cell neoplasm

[演者] Sho Kubota (久保田 翔):1
[著者] Kenji Tokunaga (徳永 賢治):2, Motohiko Oshima (大島 基彦):3, Tomohiro Umezu (梅津 知宏):4, Akinori Kanai (金井 昭教):5, Kar Ton Tan:6, Henry Yang:6, Eisaku Iwanaga (岩永 栄作):2, Norio Asou (麻生 範雄):7, Takahiro Maeda (前田 隆浩):8, Atsushi Iwama (岩間 厚志):3, Kazuma Ohyashiki (大屋敷 一馬):4, Motomi Osato (大里 元美):1,6, Goro Sashida (指田 吾郎):1
1:International Research Center for Medical Sciences, Kumamoto University, 2:Department of Hematology, Kumamoto University, 3:Department of Cellular and Molecular Medicine, Chiba University, 4:Department of Hematology, Tokyo Medical University, 5:Research Institute of Radiation Biology and Medicine, Hiroshima University, 6:Cancer Science Institute of Singapore, National University of Singapore, 7:Dept. Hematology, International Med. Center, Saitama Med. Univ., 8:Department of Community Medicine, Nagasaki University

The ubiquitin ligase STUB1 regulates stability and actibity of RUNX1 and RUNX1-RUNX1T1

[演者] Taishi Yonezawa (米澤 大志):1
[著者] Hirotaka Takahashi (高橋 宏隆):2, Shiori Shikata (四方 紫織):1, Xiaoxiao Liu (劉 瀟瀟):1, Shuhei Asada (浅田 修平):1, Tsuyoshi Fukushima (福島 剛):1, Tomofusa Fukuyama (福山 朋房):1, Yosuke Tanaka (田中 洋介):1, Tatsuya Sawasaki (澤崎 達也):2, Toshio Kitamura (北村 俊雄):1, Susumu Goyama (合山 進):1
1:The Institute of Medical Science, Tokyo Univ., Tokyo, Japan, 2:Proteo-Science Center (PROS), Ehime University, Ehime, Japan

ASCT1 contributes to survival of aerobic AML cells through enhancement of antioxidant activity

[演者] Yu Kochi (幸地 祐):1
[著者] Yoshikane Kikushige (菊繁 吉謙):1, Toshihiro Miyamoto (宮本 敏浩):1, Koichi Akashi (赤司 浩一):1,2
1:Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 2:Center for Cellular and Molecular Medicine, Kyushu University, Fukuoka, Japan

The cohesin subunit Stag2 regulates hematopoietic differentiation and self-renewal

[演者] Yotaro Ochi (越智 陽太郎):1,2
[著者] Ayana Kon (昆 彩奈):1, Kenichi Yoshida (吉田 健一):1, Keisuke Kataoka (片岡 圭亮):1, Masahiro Nakagawa (中川 正宏):1, Hideki Makishima (牧島 秀樹):1, Manabu Nakayama (中山 学):3, Haruhiko Koseki (古関 明彦):4, Akifumi Takaori-Kondo (高折-近藤 晃史):2, Seishi Ogawa (小川 誠司):1
1:Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan, 2:Department of Hematology and Oncology, Kyoto University, Kyoto, Japan, 3:Chromosome Engineering Team, Technology Development, Kazusa DNA Research Institute, 4:Laboratory for Developmental Genetics, RIKEN Center

The molecular mechanisms of NPMc and IDH2 mutant-mediated upregulation of Hoxa genes

[演者] Yoko Ogawara (小川原 陽子):1
[著者] Issay Kitabayashi (北林 一生):1
1:Div. Hematological Malignancy, Natl. Cancer Ctr. Res. Inst.